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 The incidence of fungal infections in humans is increasing worldwide because of the 
rising numbers of immunocompromised hosts, resulting from AIDS, chemotherapy for cancer 
patients, and patients receiving immunosuppressive drugs for transplantation and auto-immune 
diseases. Clinical manifestations of fungal infections may be relatively harmless (e.g. in the case 
of dermatophytes or Malassezia species), but invasive fungal infections (IFIs) can be life-
threatening (Giri, S. and Kindo, A. J., 2012; Sifuentes-Osornio, J., Corzo-Leon, D. E. et al., 
2012; Mayer, F. L., Wilson, D. et al., 2013). 
 Candida species, Aspergillus species and Cryptococcus neoformans are three main 
organisms causing invasive fungal infections in humans (Liao, Y., Chen, M. et al., 2013). 
Candida species are considered as normal flora which can be found in the oral cavity and the 
gastrointestinal tract of most healthy humans (Fidel, P. L., Jr., Vazquez, J. A. et al., 1999; 
Brunke, S. and Hube, B., 2012) and the majority of Candida isolates from clinical samples 
represent asymptomatic colonization (Brunke, S. and Hube, B., 2012). However, when the 
human body is weakened by prolonged treatment with antibiotics, diabetes, cancer, extreme age, 
immunosuppression, intravenous catheters or long-term hospitalization, these fungi can cause a 
broad range of clinical manifestations ranging from local superficial to life-threatening systemic 
infections, with high morbidity and mortality (Perlroth, J., Choi, B. et al., 2007; Brunke, S. and 
Hube, B., 2012) (Figure 1). Infections caused by Candida species are termed “candidiasis”. More 
than 90% of candidiasis cases are attributed to only five Candida species:  C. albicans, C. 
glabrata, C. parapsilosis, C. tropicalis and C. krusei. Nevertheless,  rare species of Candida are 
isolated from candidiasis patients every year such as C. guilliermondii, C. inconspicua, C. 
rugosa, and C. lambica (Pfaller, M. A., Diekema, D. J. et al., 2010; Giri, S. and Kindo, A. J., 




worldwide. The second most prevalent species depends on the site of infection and geography. 
For example, in the United States, Europe, and Asia-Pacific, C. glabrata is considered the second 
most prevalent species (Marchetti, O., Bille, J. et al., 2004; Borg-von Zepelin, M., Kunz, L. et 
al., 2007; Pfaller, M. A., Diekema, D. J. et al., 2010), but in Latin America (e.g. Brazil), C. 
tropicalis and C. parapsilosis are the most important species after C. albicans (Colombo, A. L., 
Guimaraes, T. et al., 2007). 
 In contrast to C. albicans, C. glabrata infections are very difficult to treat, as this 
organism is often highly resistant to azole antifungals. Amphotericin B and echinocandins are 
considered as effective drugs to eliminate this pathogenic yeast from the patients, but 
Amphotericin B has a lot of side effects and echinocandins is still very expensive. C. 
parapsilosis is less susceptible to echinocandins and C. krusei is fully resistant to Fluconazole 
(Table 1). Therefore, infections due to these non-albicans species are causes of increased 
morbidity and mortality (Marchetti, O., Bille, J. et al., 2004). Consequently, species 
identification in Candidiasis is essential to enable early and adequate antifungal therapy. 
 
 
Figure 1. Oral candidiasis in a 2 year old child 
 
The child suffers from acquired immunodeficiency syndrome (AIDS) after infection with human 
immunodeficiency virus (HIV) by its mother.  







Table 1. In vitro susceptibilities of antifungal drugs  
 
 
C. albicans C. glabrata  C. tropicalis C. parapsilosis C. krusei 
   
other 
Fluconazole + +/- + + - + 
Itraconazole + +/- + +/- +/- + 
Posaconazole + +/- + + + + 
Voriconazole + +/- + + + + 
Ketoconazole + + + + + + 
Amphotericin B + + + + +/- + 
Flucytosine +/- + +/- + +/- +/- 
Nystatin + + + + + + 
Echinocandins
a
 + + + - + + 
 
This data were combinated from (Richter, S. S., Galask, R. P. et al., 2005; Leventakos, K., 
Lewis, R. E. et al., 2010) 
+: in vitro activity, -: no in vitro activity, +/-: modest in vitro activity 
a
: Caspofungin, micafungin, and anidulafungin 
 
1.2 C. glabrata genetics and evolution  
 
 In the past, C. glabrata was classified in the genus of Torulopsis and termed Torulopsis 
glabrata because it was thought to be unable to form non-hyphae. Subsequently, when 
conditions for pseudohypha production in T. glabrata were discovered, the organism was 
reclassified in the genus Candida and renamed C. glabrata  (Fidel, P. L., Jr., Vazquez, J. A. et 
al., 1999). 
 C. glabrata belongs to the class Saccharomycetes in the order Saccharomycetales and the 
family Saccharomycetaceae. The yeast cells of C. glabrata are 1 to 4 µm in size and smaller than 




condition but it can produce pseudohyphae on solid synthetic low ammonia dextrose nitrogen 
starvation medium (SLAD) after incubation at 37
o
C for 2 weeks (Csank, C. and Haynes, K., 
2000). Colonies of C. glabrata on Sabouraud dextrose agar are smooth, cream colored and 
glistening. Like S. cerevisiae, C. glabrata is haploid genome yeast. In contrast, C. albicans and 
several other non-albicans Candida species are diploid (Fidel, P. L., Jr., Vazquez, J. A. et al., 
1999).   
 The genome of the reference strain C. glabrata CBS138 (originally isolated from human 
feces) has been sequenced and it shows 13 chromosomes totalling in 12.3 Mb. There are 
approximately 5,283 coding sequences (CDS), 207 tRNA genes and the genome has a G+C 
content of 38.8% (http://genolevures.org/cagl.html and (Kaur, R., Domergue, R. et al., 2005)). 
   The results from phylogenetic analyses show that C. glabrata is quite distinct from C. 
albicans and the other pathogenic Candida species, but it is closely related to S. cerevisiae 
(Figure 2) (Diezmann, S., Cox, C. J. et al., 2004; Kaur, R., Domergue, R. et al., 2005). C. 
glabrata shares a common ancestor to S. cerevisiae and clearly belongs to a clade different from 
that of other Candida species. As a consequence, the CUG codon of C. glabrata and S. 
cerevisiae is translated to leucine, but in other Candida species it is translated to Serine (Roetzer, 
A., Gabaldon, T. et al., 2011). Many genes of S. cerevisiae have orthologues in C. glabrata and 
the gene orders are largely conserved between both organisms (Roetzer, A., Gabaldon, T. et al., 
2011). However, C. glabrata displays a significantly higher degree of gene loss, resulting in a 
regressive evolution (loss of specific functions) as compared to S. cerevisiae (Dujon, B., 
Sherman, D. et al., 2004). Indeed, C. glabrata lacks the genes that are involved in galactose and 
sucrose assimilation, phosphate, nitrogen, and sulfur metabolism and chemical biosynthesis of 
nicotinic acid, thiamine and pyridoxine (Kaur, R., Domergue, R. et al., 2005).  
 The adhesin genes of C. glabrata (e.g. Epa protein family) and S. cerevisiae (Flo protein 
family) locate in subtelomeric regions of the chromosomes. Since both adhesin families share 
some degree of functional homology and the tandem repeat motifs of several Epa and Flo 
proteins are similar (Roche, 2007). Thus, it is assumed that the FLO and EPA genes are 
evolutionarily related but their sequences have diverged beyond recognition. However, Epa 
adhesin from C. glabrata may have occured from adaptation because of the survival within 







Figure 2. Fungal phylogenetic tree of ascomycetous taxa 
 
Phylogenetic tree based on a combined analysis of the nuclear 18S rDNA and 26 rDNA of 
ascomycetous taxa. The nodes marking the Euascomycetes, Archiascomycetes, and 
Hemiascomycetes as well as many terminal branches are supported by homogeneous Bayesian 
posterior probabilities 95%. Black arrows indicate the origins of the three classes of the phylum 
Ascomycota. Red arrows indicate C. albicans and C. glabrata and S. cerevisiae (modified from 




Table 2. Comparison of C. glabrata, C. albicans and S. cerevisiae 
 
 C. glabrata C. albicans S. cerevisiae 
Number of 
chromosomes 
13 chromosomes 8 chromosomes 16 chromosomes 
Length of DNA 12.3 Mb 14.3 Mb 12.1 Mb 
Coding genes 5,283 6,202 5,807 
Ploidy Haploid (n) Diploid (2n) Diploid (2n) 
CUG codon Leucine Serine Leucine 











Mating genes Present Present Present 
Sexual cycle Unknown Known Known 
Clonal population 
structure 
Yes Yes No 
Phenotypic switching Present Present Absent 
True hyphae Absent Present Absent 
Pseudohyphae Present Present Present 
Biofilm formation Present Present Present 
Major adhesins Epa family  Hwp1 and Als 
family  
Flo family  
Auxotrophy Niacin, thiamine, 
pyridoxine 
None None 
Azole resistance Innate resistance Susceptible Susceptible 
Mitochondrial function Petite positive Petite negative Petite positive 
 





1.3 Pathogenesis and virulence factors of C. glabrata  
  
 Normally, C. glabrata is a commensal microorganism in the human body, but when the 
host’s immune system is compromised, it can also cause severe infections. On mucosal surfaces, 
C. glabrata colonizes by expressing specific adherence-genes such as the CgEPA family, 
CgSilent Information Regulator (SIR3), and CgPyrazinamidase and NiCotinamidase (PNC1) 
enabling it to form biofilms. C. glabrata also has an evasive strategy to manage phagocytosis by 
macrophages. After uptake, macrophages initially induce formation of peroxisomes. These 
peroxisomes are degraded by C. glabrata using the pexophagy pathway, a specific subtype of 
autophagy. The autophagy related CgAuTophaGy (ATG) gene family contributes to the survival 
of C. glabrata during engulfment and this process requires mobilization of resources to survive 
in phagosome. C. glabrata is relative resistant to carbon starvation (Roetzer, A., Gabaldon, T. et 
al., 2011). Carbon starvation of engulfed C. glabrata is associated with the up-regulation of 
CgIsoCitrate Lyase (ICL1) and CgMaLate Synthase (MLS1) genes in the glyoxylate cycle 
(Fukuda, Y., Tsai, H. F. et al., 2013). The oxidative burst response in phagosomes of 
macrophages is administrated by neutralization of the oxidative reaction and increase the pH in 
phagosome for the survival of C. glabrata. Both reactions contribute to activation of CgYeast AP 
(YAP1), a transcription factor responsive to H2O2 and CgSuperOxide Dismutases (SOD1). 
Fequently, C. glabrata strains are resistant to antifungal drugs, especially fluconazole, mediated 
through efflux pumps CgPDR1 and CgCDR1 (Ferrari, S., Sanguinetti, M. et al., 2011; Roetzer, 








Figure 3. Hypothetical model of C. glabrata pathogenesis 
 
C. glabrata is found as normal flora in mucosal areas of humans, such as the gut. In 
immunocompromised or elderly persons, C. glabrata is able to spread into tissues and cause 
organ failure. The control of phagocytes is necessary for elimination of the invading C. glabrata. 
The right panel shows a list of genes that contribute to each stage of C. glabrata infection 
(Figure taken from (Roetzer, A., Gabaldon, T. et al., 2011)). 
 
 
1.4 Cell wall structure of C. glabrata 
 
1.4.1 The polysaccharide backbone of the C. glabrata cell wall 
 
 The cell wall of fungi is one of the most important organelle. It determines cell shape, 
physical strength and limits permeability. Furthermore, it contributes to adherence to host cells 
or medical materials and to biofilm formation. The cell wall can be considered a “virulence 
associated factor”, since it determines the initial host – fungus interactions leading to mycoses. 
Moreover, the cell wall triggers the human immune response, especially the innate immunity and 
it is also connect to antifungal drug resistance (Weig, M., Jansch, L. et al., 2004; de Groot, P. W., 




 Generally, the fungal cell wall consists of 80-90% polysaccharides, mainly glucans and 
mannans. In yeast cell wall, the outer layer cell wall is highly enriched with O- and N-linked 
mannans that are covalently associated with proteins to form glycoproteins, whereas the inner 
layer contains the skeletal polysaccharides chitin and β-1,3-glucan, which confer strength and 
cell shape. The outer cell wall proteins are attached to this inner wall framework predominantly 
by glycosylphosphatidylinositol (GPI) remnants that are linked to the skeleton through a more 
flexible β-1,6-glucan. The cell wall of molds, e.g. Aspergillus fumigatus, it is composed of a 
unique β-1,3/1,4-glucan skeleton with chitin and galactomannan covalently linked to the 
nonreducing ends of β-1,3-glucan. The cell wall is mainly coated with GPI proteins, which 
contain N- and O-glycans (Jin, C., 2012). In comparison, the cell walls of molds have a higher 
complexity of carbohydrates and chitin components than yeast.  
  The cell wall of C. glabrata contains approximately 54% glucans, 43.8% mannans, 1.2% 
chitin, and 6.4% proteins (Table 3) and the architecture of the cell wall in C. glabrata is shown 
in Figure 4.  
 In summary, the cell wall of C. glabrata displays a high level of proteins and mannans, 
but a low level of chitin and glucan, including 1,6-β-glucan and 1,3-β-glucan, when compared 
with S. cerevisiae and C. albicans (de Groot, P. W., Kraneveld, E. A. et al., 2008). Therefore, it 












Figure 4. Structure of the yeast cell wall 
 
The outer layer of the cell wall is highly enriched with O- and N-linked mannose polymers 
(mannans) that are covalently associated with proteins to form glycoproteins, whereas the inner 
layer contains the skeletal polysaccharides chitin and β-1,3-glucan, which confer strength and 
cell shape. The outer cell wall proteins are attached to this inner wall framework predominantly 
by glycosylphosphatidylinositol (GPI) remnants that are linked to the skeleton through a more 
flexible β-1,6-glucan. Figure was taken from (Gow, N. A., van de Veerdonk, F. L. et al., 2012). 
 
 
Table 3. Cell wall composition of C. glabrata in comparison to  S. cerevisiae and C. albicans 
 
Organisms Cell wall content  
 
Protein (%) Chitin (%) Man (%) Glu (%) M/G 
Alkali-insoluble glucan 
(%) 
           1,6-β 1,3-β 
C. glabrata  6.4 ± 0.1 1.2 ± 0.1 43.8 ± 0.5 54.0 ± 0.2 0.81 4.2 ± 0.1 16.7 ± 1.7 
S. cerevisiae  4.0 ± 0.1 1.4 ± 0.2 34.2 ± 1.6 60.3 ± 2.5 0.57 7.1 ± 0.2 26.8 ± 0.9 
C. albicans  3.5 ± 0.2 4.2 ± 0.1 26.6 ± 2.3 64.0 ± 4.9 0.42 10.6 ± 0.6 26.2 ± 1.1 
 
Cell wall content values are from exponentially growing cells (in YPD) and are expressed as 
percentages of freeze-dried cell walls. Man: mannose, Glu: glucose, M/G: ratio of mannose to 






1.4.2 The cell wall proteome of C. glabrata  
 
 Covalently linked wall protein of C. glabrata can be divided 2 groups as (i) GPI cell wall 
proteins, which can be specifically released with HF-pyridine and (ii) mild alkali-soluble cell 
wall proteins, which can be released by mild NaOH (Klis, F. M., Brul, S. et al., 2010). The 
majority of cell wall proteins are linked to the carbohtdrate complex via a covalent bond of a 
sugar remnant of their GPI anchor and 1,6-β-glucan. The minority of cell wall proteins are 
attached to 1,3-β-glucan through a linkage which sensitive to mild alkali. The covalently linked 
wall proteins have a variety of function as (i) carbohydrate-active enzyme such as Crh1, Scw4, 
and Gas family, (ii) other enzymatic activity such as Plb2, (iii) nonenzymatic cell wall proteins 
such as Cwp family, Pir family, and Ssr1, and (iv) adhesin such as Epa family, and Awp family 
(de Groot, P. W., Kraneveld, E. A. et al., 2008). 
 The most abundant covalently linked wall proteins of C. glabrata were identified by 
LC/MS/MS as Cell Wall Protein (Cwp) 1 family. This proteins are structural cell wall proteins 
that connected to the cell wall either through the GPI anchor and alkali sensitive linkage 
(Schmidt, P., 2007; de Groot, P. W., Kraneveld, E. A. et al., 2008).  
 In silico analysis in C. glabrata  revealed that there are 106 glycosylphosphatidylinositol-
modified (GPI) proteins in the cell wall and 50% of these GPI proteins have features of adhesin-
like Cell Wall Proteins (CWPs) (Weig, M., Haynes, K. et al., 2001; Weig, M., Jansch, L. et al., 
2004; de Groot, P. W., Kraneveld, E. A. et al., 2008) 
 One of the noticeable characteristics of Candida spp. is their ability to firmly adhere to 
host surface cells, including the human skin, endothelial, and epithelial mucosal host tissues. 
Adhesion is considered an important first step of pathogenesis in fungal infections. Candida spp. 
also attach to medical abiotic surfaces such as intravascular and urinary catheters, prosthetic 
cardiac valves, and denture prostheses (Busscher, H. J., Rinastiti, M. et al., 2010; de Groot, P. 
W., Bader, O. et al., 2013). Most of known fungal adhesins are large (usally more than 800 
amino acids) GPI-modified wall proteins. In silico analyses showed that C. glabrata has 
significantly more potential adhesin genes than C. albicans and S. cerevisiae. Two-thirds of these 
66 putative adhesin genes in C. glabrata are situated in regions of subtelomeres. In all 
subtelomeric parts of reference strain CBS138 at least one of putative adhesin gene is present (de 




 A well-known adhesin family of C. glabrata is the Epa (epithelial adhesion protein) 
family with 17 members in reference strain CBS138. The reference strain BG2 has two 
additional EPA genes EPA4 and EPA5 (Kaur, R., Domergue, R. et al., 2005; de Groot, P. W., 
Bader, O. et al., 2013). Additionally, none of the orthologous EPA genes in either strain are 
100% identical. The EPA family is associated with adhesion to human epithelial and endothelial 
cells, particularly EPA1, EPA6 and EPA7 (Domergue, R., Castano, I. et al., 2005; Kaur, R., 
Domergue, R. et al., 2005). Data from Bader et al. revealed that ten progenies of the C. glabrata 
CBS138/ATCC2001 reference strain had a divergent expression of EPA family genes, resulting 
in altered adhesion properties. The low adherence strain CBS138/6 showed significant lower 
expression of EPA3, EPA6, EPA7 and EPA22 when compared to the other progenies (Bader, O., 
Schwarz, A. et al., 2012) indicating that the regulation of adhesins in C. glabrata is very 
dynamic. This adaptability may enable individual strains to adjust to different host cell 
conditions (Kraneveld, E. A., de Soet, J. J. et al., 2011).  
The N-terminal part of the Epa proteins contain the binding domains that are similar in 
sequence to the so-called PA14 domains (anthrax protective antigen). Studies with glycan arrays 
indicated that PA14 of Epa1, Epa6 and Epa7 bind to oligosaccharides with terminal galactose 
residues, as they are found in mucin-type O-glycans (Zupancic, M. L., Frieman, M. et al., 2008). 
This finding supports the idea that Epa proteins can directly bind to glycoproteins on the surface 
of host cell (de Groot, P. W., Bader, O. et al., 2013). 
 Another important adhesin family in C. glabrata is the Pwp family. It consists of seven 
members that are lectins (de Groot, P. W., Bader, O. et al., 2013). In vitro studies showed that 
Pwp7 plays a role in adherence to human endothelial cells (Desai, C., Mavrianos, J. et al., 2011). 
Additionlly, six further non-Epa adhesin-like wall proteins were found in the C. glabrata cell 
wall, namely Awp1 to Awp6 (de Groot, P. W., Kraneveld, E. A. et al., 2008; Kraneveld, E. A., 
de Soet, J. J. et al., 2011). Awp1 is upregulated during biofilm development, and Awp6 was 
identified by mass spectrometric analysis in cell wall preparations of biofilms. It is assumed that 
expression of these adhesins depends on many factors which seem to be dependent on the 
genetic strain background, environmental growth conditions and aggregation (Kraneveld, E. A., 
de Soet, J. J. et al., 2011; de Groot, P. W., Bader, O. et al., 2013). However, the exact function 




1.4.3 Ecm33 protein family  
 
 The Ecm33 protein family in C. glabrata consists of at least four members as Ecm33 
(CAGL0M01826g), Pst1 (CAGL0E04620g), Sps2 (CAGL0H01661g), and Sps22 
(CAGL0B00616g). Ecm 33 and Pst1 were found to be very abundant proteins in the cell wall of 
C. glabrata (de Groot, P. W., Kraneveld, E. A. et al., 2008). However, the exact function of the 
Ecm33 protein family is still unclear. Previous scientific evidences revealed that this family may 
play a role in cell wall remodeling, cell wall maintenance and cell biogenesis (de Groot, P. W., 
Ruiz, C. et al., 2001) in the ascomycocetes including S. cerevisiae (Pardo, M., Monteoliva, L. et 
al., 2004), C. albicans (Martinez-Lopez, R., Monteoliva, L. et al., 2004; Martinez-Lopez, R., 
Park, H. et al., 2006) and A. fumigatus (Chabane, S., Sarfati, J. et al., 2006). 
 In S. cerevisiae, deletion of ECM33 (YBR078w) resulted in hypersensitivity to cell wall 
perturbing agents and an increased amount of 1,6-β-glucan-linked proteins secreted to the culture 
medium. The deletion of PST1 (YDR055w), which is a homologue of ECM33, did not show these 
effects. However, synergistic effects affecting the cell wall were found in the double gene 
deletion mutant of ECM33 and PST1. The single gene deletion in ECM33 and the double gene 
deletion in ECM33 and PST1 resulted in a stimulation of phosphorylation in Slt2 protein which 
is a signaling controller of cell wall integrity (Pardo, M., Monteoliva, L. et al., 2004). 
 In C. albicans, the deletion mutant of ECM33 (orf19.3010.1) was sensitive to cell wall 
perturbing agents. It failed to form filaments in Spider medium and its blastospores were larger 
and more flocculated when compared to the wild-type strain. The cell wall architecture of the 
Δecm33 mutant was abnormal because of the thickness of the internal layer of 1,3-β-glucan and 
chitin. ECM33 deletion reduced the adherence and invasion capacity to endothelial cells and the 
FaDu oral epithelial cell line. Moreover, the Δecm33 mutant showed less virulence in a murine 
model indicating that the CaEcm33 protein plays a role in C. albicans virulence (Martinez-
Lopez, R., Monteoliva, L. et al., 2004; Martinez-Lopez, R., Park, H. et al., 2006; Martinez-
Lopez, R., Nombela, C. et al., 2008; Rouabhia, M., Semlali, A. et al., 2012).  
 In the filamentous fungus A. fumigatus, the deletion of ECM33 results in altered 
phenotypes as compared to the wild-type strain: (i) rapid conidial germination (ii) a defect in 
conidial separation, (iii) an increase of conidia size with an increase in the amount of chitin in the 




resistance to the cell pertubing agents, (vi) conidia were more resistant to killing by phagocytes, 
whereas the mycelium was more easily killed by neutrophils, and (vii) increased virulence in a 
mouse model. These results suggest that the AfEcm33 protein contributes in key aspects of cell 
wall morphogenesis, cell wall integrity and plays a role in A. fumigatus virulence (Chabane, S., 
Sarfati, J. et al., 2006) (Romano, J., Nimrod, G. et al., 2006).  
 These primliminary findings indicate that the functionanl role of Ecm33 in S. cerivisiae is 
different from the function in A. fumigatus. However, so far there is no study that determinated 
the function of the abundant Ecm33 cell wall protein in the human pathogen C. glabrata.  
 
 
Table 4. The effects of ECM33 deletion in S. cerevisiae, C. albicans, and A. fumigatus 
 









    1. Shape and size rounder and larger rounder and larger larger 
2. Cell perturbing agents sensitive sensitive resistant 
3. Cell wall architecture
 
 
increased 1,3 and 1,6-β-
glucan levels 
increased 1,3-β-glucans 
and chitin levels  
increased chitin level 
  
4. Hypha production N/A absenta faster 
5. Growth rate ND 2-fold reduced increased 
6. Flocculation ND yes yes 
7. Adherence in cell lines ND decreased no significant difference 
8. Pathogenicity in mouse N/A decreased increased  
 
*: parental strain in each organism was used to compare a difference of phenotype. 
1
: (Pardo, M., Monteoliva, L. et al., 2004), 
2-4
: (Martinez-Lopez, R., Monteoliva, L. et al., 2004; 
Martinez-Lopez, R., Park, H. et al., 2006; Martinez-Lopez, R., Nombela, C. et al., 2008), and 
5-6
: 
(Chabane, S., Sarfati, J. et al., 2006; Romano, J., Nimrod, G. et al., 2006) 
N/A: not applicable, ND: not determined. 
a











1.5 Aims of the study 
 
 C. glabrata is the second most frequently observed yeast in clinical specimen. In 
comparison to C. albicans infections, candidiasis caused by C. glabrata is more difficult to treat 
because this species is often resistant to azole antifungals and displays a high degree of adhesive 
capacities on clinically used catheter materials, facilitating the formation of biofilms.  
 Proteins of the Ecm33/Pst1 family in C. glabrata were experimentally shown to be highly 
abundant cell wall proteins of this organism. Previous studies indicate that the ECM33 homologs 
in S. cerevisiae, C. albicans and A. fumigates are associated with integrity and architecture of the 
cell wall, adherence capacity, growth rate and with virulence, but the true molecular function of 
the proteins in these organisms is unknown. Furthermore, phenotypic analysis of ECM33 
deletion mutants in the different species indicates that the functional role of Ecm33 homologs 
might be different between the organisms. In C. glabrata the cell wall is of particular interest, 
because it holds key functions such as adhesion and detoxification of immune responses (e.g. the 
oxidative burst of attacking macrophages) during pathogenesis. Therefore, this study focuses on 
the characterization of the Ecm33 protein family of C. glabrata, where the cell wall architecture 
is significantly different to otherwise closely related fungi. In C. glabrata, this family consists of 
four members: Ecm33, Pst1, Sps2, and Sps22. 
 The aims of the present study were (i) to generate molecular tools for the study of this 
gene family in C. glabrata such as mutants, revertants, complemented strains, recombinant 
Ecm33-family proteins, and anti-Ecm33 antibodies, (ii) to characterize the function of Ecm33 
and Pst1 of C. glabrata in relation to their orthologs in C. albicans and S. cerevisiae via 
comparison of the phenotypic differences among the ECM33 and PST1 deleted mutants and 
wild-type in all three organisms, and (iii) to gather data on the biological function of Ecm33 











 Disposables were purchased from Sarstedt (Nümbrecht, Germany), Greiner bio-one 




- General chemicals were purchased from Roth (Karlsruhe, Germany), Merck (Darmstadt, 
Germany), and Sigma-Aldrich (Munich, Germany). 
- Restriction enzymes were purchased from New England BioLabs Inc (Frankfurt am Main, 
Germany). 
- PCR purification and agarose gel extraction kits were purchased from Qiagen (Hilden, 
Germany) 
- DNA and protein weight standards were purchased from Fermentas (Vilnius, Lithuania) 
- Oligonucleotides were purchased from Sigma-Aldrich (Munich, Germany). 
- Reagents for Real-time PCR (LightCycler
®





 All liquid media were sterilized at 121°C for 15 minutes or by filtration (0.22µm pore 
size) and were kept at 4°C.   
 
LB  1% [w/v] Bacto-tryptone, 0.5% [w/v] yeast extract, 0.5% [w/v] NaCl, 2% [w/v]   




  For selection LB media, ampicillin (100 µg/ml) or Zeocin
TM
 (25 µg/ml) was  
  added into media after autoclaving. 
YPD   1% [w/v] yeast extract, 2% [w/v] peptone, 2% [w/v] dextrose, 2% [w/v]    
  agar (for YPD agar) in ddH2O. 
  For selection YPD media, Zeocin
TM
 (200 µg/ml) was added into media after  
  autoclaving. 
MM  1.34% [w/v] YNB, 2% [w/v] dextrose, 0.006% [w/v] histidine, 0.008% [w/v]  
  leucine, 0.026% [w/v] tryptophan, 2% [w/v]  agar (for MM agar) in ddH2O. 
RPMI 1640 1.04% [w/v] RPMI-1640, 2% [w/v] dextrose, 3.453% [w/v] 3-(N-morpholino)- 
  propanesulphonic acid (MOPS) in ddH2O. 
BMMH 100 mM potassium phosphate pH6, 1.34% [w/v] YNB with ammonium sulfate,  




Table 5. Plasmids used in this study 
 
Code Plasmid Source 
P1 pQE30 Qiagen 
P2 pQE30:CgECM33 This study 
P3 pPICZα Invitrogen 
P4 pPICZα:CgECM33 This study 
P5 pPICZα:CgPST1 This study 
P6 pBM51-Leu Schwarzmüller T., Vienna* 
P7 pBM51-Leu:CgECM33 This study 
P8 pBM51-Leu:CgPST1 This study 
P9 pBM51-Leu:CgSPS2 This study 
P10 pBM51-Leu:CgSPS22 This study 
P11 pBM51-Leu:truncated CgECM33 This study 
P12 pBM51-Leu:ScECM33 This study 
P13 pBM51-Leu:CaECM33 This study 
 






2.5 E. coli strains  
 
Table 6. E. coli strains used in this study 
 
Code Strains Plasmid Gene of interest Description 
1 DH5α - - Empty host 
1.1 BL-21 - - Empty host 
1.2 Rosetta - - Empty host 
2 DH5α pQE30 - Amplification of pQE30 
3 DH5α pPICZα - Amplification of pPICZα 
4 DH5α pPICZα CgECM33 Amplification of pPICZα:CgECM33  
5 DH5α pPICZα CgPST1 Amplification of pPICZα:CgPST1  
6 DH5α pQE30 CgECM33 Amplification of pQE30:CgECM33 
7 BL-21 pQE30 CgECM33 Expression of Ecm33p in E. coli 
8 Rosetta pQE30 CgECM33 Expression of Ecm33p in E. coli 
11 DH5a pBM51-Leu - Amplification of pBM51-Leu 
15 DH5a pBM51-Leu ECM33 Amplification of pBM51-Leu:CgECM33 for revertant construction 
17 DH5a pBM51-Leu PST1 Amplification of pBM51-Leu:CgPST1 for revertant construction 
25 DH5α pBM51-Leu ScECM33 Amplification of pBM51-Leu:ScECM33 for complemented strain construction 
26 DH5α pBM51-Leu CaECM33 Amplification of pBM51-Leu:CaECM33 for complemented strain construction 
27 DH5α pBM51-Leu truncated CgECM33 Amplification of pBM51-Leu:truncated CgECM33 for complemented strain construction 
28 DH5α pBM51-Leu CgSPS2 Amplification of pBM51-Leu:CgSPS2 for complemented strain construction 





2.6 Yeast strains  
 
Table 7. Yeast strains used in this study 
 
Code Organisms Strains Source and reference Description 
Y15 P. pastoris X33 Invitrogen Wild-type 
Y16 P. pastoris GS115 Invitrogen his4 
Y17 P. pastoris KM71H Invitrogen arg4aox1:ARG4 
Y18 P. pastoris GS115:Albumin Invitrogen Control for secreated protein 
Y19 P. pastoris GS115:LacZ Invitrogen Control for intracellular protein 
Y20 P. pastoris GS115: 1,6-β-glucanase Bom IJ., Vlaardingen
1
 1,6-β-glucanase 
Y21 P. pastoris GS115:CgECM33  This study Ecm33 protein expression 
Y22 P. pastoris GS115:CgPST1 This study Pst1 protein expression 
Y23 P. pastoris X33:CgECM33  This study Ecm33 protein expression 
Y24 P. pastoris X33:CgPST1 This study Pst1 protein expression 
Y25 S. cerevisiae Auxotroph BY4741 Gil C., Madrid
2
 Background wild-type 
Y26 S. cerevisiae Δecm33 Gil C., Madrid2 FBEHO41-01A 
Y27 S. cerevisiae Δecm33 Gil C., Madrid2 BY4741 
Y28 S. cerevisiae Δpst1 Gil C., Madrid
2
 BY4741 
Y29 S. cerevisiae Δpst1/Δecm33, YP1-10C Gil C., Madrid
2
 FBEHO41-01A 
Y30 S. cerevisiae Δpst1/Δecm33, YP1-1B Gil C., Madrid
2
 FBEHO41-01A 
Y31 C. albicans Clinical strain NRZ, Göttingen Pathogen 
Y34 C. glabrata CBS138/ATCC2001 Schwarzmüller T., Vienna
3
 Wild-type 
Y35 C. glabrata Auxotroph Δhtl Schwarzmüller T., Vienna
3
 Background wild-type 
Y36 C. glabrata Δpst1 Schwarzmüller T., Vienna Single deletion mutant 
Y37 C. glabrata Δecm33 Schwarzmüller T., Vienna Single deletion mutant 





Table 7. Yeast strains used in this study (continued) 
 
Code Organisms Strains Source or reference Description 
Y43 C. glabrata Δpst1:CgPST1 This study Completed revertant 
Y45 C. glabrata Δecm33:CgECM33 This study Completed revertant 
Y47 C. glabrata Δpst1/Δecm33:CgPST1 This study Incompleted revertant 
Y49 C. glabrata Δpst1/Δecm33:CgECM33 This study Incompleted revertant 
Y51 C. albicans Auxotroph Caf2 Gil C., Madrid
4
 Background wild-type 
Y53 C. albicans Δecm33:Δecm33 Gil C., Madrid
4
 Homozygous mutant 
Y55 C. albicans Δecm33:Δecm33:ECM33:ECM33 Gil C., Madrid
4
 Revertant 
Y60 C. glabrata Δecm33:ScECM33 This study Complemented strain 
Y62 C. glabrata Δecm33:CaECM33 This study Complemented strain 
Y64 C. glabrata Δecm33:CgPST1 This study Complemented strain 
Y65 C. glabrata Δecm33:truncated CgECM33 This study Complemented strain 
Y67 C. glabrata Δecm33:CgSPS2 This study Complemented strain 
Y68 C. glabrata Δecm33:CgSPS22 This study Complemented strain 
 
1
: (Bom, I. J., Dielbandhoesing, S. K. et al., 1998) 
2
: (Pardo, M., Monteoliva, L. et al., 2004) 
3
: (Schwarzmüller, T., 2009) 
4
: (Martinez-Lopez, R., Monteoliva, L. et al., 2004). 









2.7 Oligonucleotides  
 
Table 8. Oligonucleotides used in this study 
 
Code Name Sequence Description 
1 F-CG-LM CCGAATTCCAGAACTCTACATCTGACGATGTTCC Ecm33p expression in Pichia pastoris; EcoRI 
2 R-CG-LM CAGGTACCAGACTTCTTGGTCTTGGTGGAGGA Ecm33p expression in Pichia pastoris; KpnI 
3 F-CG-LE CCGAATTCGCTAACACTACAGTCCCAGATGTT Pst1p expression in Pichia pastoris; EcoRI 
7 CG-LE-XbaI CCTCTAGAAGCACCCTTGGACTTCTGCT Pst1p expression in Pichia pastoris; XbaI 
8 For-AOX1 GACTGGTTCCAATTGACAAGC Checking of  the insert fragment size in pPICZα 
9 Rev-AOX1 GCAAATGGCATTCTGACATCC Checking of  the insert fragment size in pPICZα 
10 alpha-Factor TACTATTGCCAGCATTGCTGC Checking of  the insert fragment size in pPICZα 
11 hk2 CGTCAAGACTGTCAAGGAGGG Checking of  the mutant clones 
12 hk3 CATCATCTGCCCAGATGCGAAG Checking of  the mutant clones 
13 F-MuE-Cont AGCGTTTATTTGGTAGAAGGTG Checking of  the mutant clones 
14 R-MuE-Cont CTTCAAGTCCTGAAAGTTGC Checking of  the mutant clones 
15 F-MuM-Cont GATATGATGGATCCCGTGTC Checking of  the mutant clones 
16 R-MuM-Cont TTTTATGGGTTCCATCAGAG Checking of  the mutant clones 
17 F-LM-pQE CCGGATCCCAGAACTCTACATCTGACGATGTTCC Ecm33p expression in E.coli; BamHI 
18 R-LM-pQE CACTGCAGAGACTTCTTGGTCTTGGTGGAGGA Ecm33p expression in E.coli; PstI 
19 RT-ECM33-F CAACACCGTCTCCGGTAACT Reverse transcription-Real time-PCR 
20 RT-ECM33-R GTCTTGGTGGAGGAAGTGGA Reverse transcription-Real time-PCR 
21 RT-PST1-F CCGTCTCCTTCGCTAACTTG Reverse transcription-Real time-PCR 
22 RT-PST1-R AGAAGTTACCGGCCTTGGTT Reverse transcription-Real time-PCR 
23 RT-SPS2-F CAATTGTTAGAGGCGGGAAA Reverse transcription-Real time-PCR 
24 RT-SPS2-R TCGCGCTGTTCTCTTGTCTA Reverse transcription-Real time-PCR 
25 RT-SPS22-F TTCCGGTGGTCTCATGATCT Reverse transcription-Real time-PCR 
26 RT-SPS22-R CTACGGACTTGCCCCTGATA Reverse transcription-Real time-PCR 
27 RT-ACT1-F TTCCAGCCTTCTACGTTTCC Reverse transcription-Real time-PCR 
28 RT-ACT1-R TCTACCAGCAAGGTCGATTC Reverse transcription-Real time-PCR 
29 RT-SLT2-F AATTTGTGATTTCGGGCTTG Reverse transcription-Real time-PCR 





Table 8. Oligonucleotides used in this study (continued) 
 
Code Name Sequence Description 
31 1F-Rev-ECM CCCTCGAGATGAAGGTCACATCATTGGT Generation of ECM33 revertant; XhoI 
32 2R-Rev-ECM CAGGATCCTCATAGCAAAGCGACGGCGA Generation of ECM33 revertant; BamHI 
33 3F-Rev-PST CCCTCGAGATGCAATTGAATCATCTTTTG Generation of PST1 revertant; XhoI 
34 4R-Rev-PST CAGGATCCCTATATTAGAGCCAAAGCAAC Generation of PST1 revertant; BamHI 
43 M13 F GTAAAACGACGGCCAGT For Topo2.1 sequencing 
44 M13 R CAGGAAACAGCTATGAC For Topo2.1 sequencing 
53 F-Seq GTTTTCCCAGTCACGACGTT Checking of the inserted fragment in pBM51-Leu 
54 R-Seq CCAAGGGGGTGGTTTAGTTT Checking of the inserted fragment in pBM51-Leu 
57 F_Ca_Xho CACTCGAGATGCAATTCAAGAACATTCTTGC Generation of CaECM33 complemented strain; XhoI 
58 R_Ca_Bam CAGGATCCTTAGAATAAAGCAACACCAACAGC Generation of CaECM33 complemented strain; BamHI 
61 F_Sc_Xho CACTCGAGATGCAATTCAAGAACGCTTTGAC Generation of ScECM33 complemented strain; XhoI 
62 R_Sc_Bam CAGGATCCTTATAGTAAGGCAACGCCAACAG Generation of ScECM33 complemented strain; BamHI 
69.2 F-CgSps22_Sal CCGTCGACATGAAGCTTATTTTTGTTGC Generation of CgSPS22 complemented strain; SalI 
70 R-CgSps22_Bam CCGGATCCCTAAAAAAATAGTGCACTCG Generation of CgSPS22 complemented strain; BamHI 
71.2 F-CgSps2_Xho CACTCGAGATGCACTGCAAGTCACCAAAC Generation of CgSPS2 complemented strain; XhoI 
72 R-CgSps2_Bam CCGGATCCTTAAAACAGTATCAAATACATG Generation of CgSPS2 complemented strain; BamHI 
75 R_truncatedECM CAGGATCCAGACTTCTTGGTCTTGGTGGAGGA Generation of truncated CgECM33 complemented strain; BamHI 
76 RT-R-Ca GAACGGTGCCACATCTACCT Reverse transcription-Real time-PCR 
77 RT-F-Ca CTGGAGCAGCACCCTTAGAC Reverse transcription-Real time-PCR 
78 RT-R-Sc TGCTAACGGTTCATTTGCTG Reverse transcription-Real time-PCR 










2.8 In silico analysis 
 
 Ecm33, Pst1, Sps2, and Sps22 protein sequences of C. glabrata were taken from 
Genomic Exploration of the Hemiascomycete Yeasts (http://www.genolevures.org) and aligned 
with MEGA4 program. Signal peptide were predicted by using SignalP 
(http://www.cbs.dtu.dk/services/SignalP/). Omega sites for GPI anchor attachment were 
predicted by using the big-PI Predictor server (http://mendel.imp.ac.at/gpi/gpi_server.html).  
 The following programs were used in this study: 
 Saccharomyces Genome Database (SGD) (http://www.yeastgenome.org) 
 Candida Genome Database (CGD) (http://www.candidagenome.org) 
 Genomic Exploration of the Hemiascomycete Yeasts (http://www.genolevures.org) 
 Basic Local Alignment Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov) 
 The translation of a nucleotide (DNA/RNA) sequence to a protein sequence 
(http://web.expasy.org/translate/) 
 Protein Molecular Weight Calculator 
(http://www.sciencegateway.org/tools/proteinmw.htm) 
 NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/) 
 Oligo Calc: Oligonucleotide Properties Calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) 
 Primer 3 program for designing PCR primers (http://frodo.wi.mit.edu) 
 PlasMapper Version 2.0 for plasmid drawing 
(http://wishart.biology.ualberta.ca/PlasMapper/index.html) 
 SignalP 4.1 server for signal peptide prediction 
(http://www.cbs.dtu.dk/services/SignalP/) 









2.9 Generation of knock out strains 
 
 The two single mutants of PST1 (Δpst1) and ECM33 (Δecm33) and the PST1/ECM33 
double mutant (Δpst1/Δecm33) in C. glabrata were generated and provided by Tobias 
Schwarzmüller, Vienna, Austria. 
 Briefly, fusion PCR was used to generate both single mutants and double mutant. The 
dominant marker NAT1 was amplified from plasmid pJK863 (Shen, J., Guo, W. et al., 2005) with 
primers fp_NAT1-U2 (5’-CGTACGCTGCAGGTCGACagcttgcctcgtccccgccg-3’) and rp_NAT1-
D2 (5’-CTACGAGACCGACACCGctggatggcggcgttagtatcg-3’) to add the two 20 bp adaptor 
sequences U2 and D2. The PCR product was ligated into pGEM-T vector (Promega, Mannheim, 
Germany), generating plasmid pTS50.  
  Fusion PCR was used to generate the deletion cassettes (Wach, A., 1996; Noble, S. M. 
and Johnson, A. D., 2005) (Figure 5 A). The 500 bp long flanking homology regions were 
amplified from C. glabrata strain ATCC2001 genomic DNA with primer pairs 5’5’/5’3’ and 
3’5’/3’3’ adding the adaptor sequence (U1/D1) of 20 bp and purified by ethanol precipitation. A 
50 µl reaction (50 mM KCl, 10 mM Tris-HCl (pH 9.0, 25°C), 0.1% TritionX-100, 1.5 mM 
MgCl2, 0.2 µM dNTPs, 0.5 µM each primer, 1 unit Taq-Polymerase and genomic wild-type 
DNA from strain ATCC2001) was subjected to cycling (93°C for 5 minutes, 35 cycles 93°C for 
30 seconds, 45°C for 30 seconds, 72°C for 90 seconds, finally 10 minutes at 72°C) in a 
thermocycler machine.  
 The dominant marker NAT1 was amplified from plasmid pTS50 in a separated PCR 
reaction using primers 5M and 3M, adding unique barcode tags and complementary U1 and D1 
adaptor sequences (Figure 5 B). The marker fragment was gel-purified over a 0.7% agarose gel. 
A 50 µl reaction (50 mM KCl, 10 mM Tris-HCl (pH 9.0, 25°C), 0.1% TritionX-100, 1.5 mM 
MgCl2, 0.2 µM dNTPs, 0.5 µM each primer, 1 unit Taq-Polymerase and plasmid TS50) was 
subjected to cycling (93°C for 3 minutes, 32 cycles 93°C for 30 seconds, 49°C for 30 seconds, 
72°C for 2.5 minutes, finally 10 minutes at 72°C) in a thermocycler machine. 
 The fusion PCR was carried out in a 50 µl volume with the same condition as above (1x 
ExTaq buffer, 0.2 µM dNTPs, 0.5 µM each primer, 2.5 units ExTaq-Polymerase (TaKaRa, 
Darmstadt, Germany) and 3 µl marker fragment, and 1.25 µl each flanking homology fragment) 




seconds, 72°C for 3 minutes, finally 10 minutes at 72°C.) The final deletion construct was 
purified by ethanol precipitation (Schwarzmüller, T., 2009). 
 
 
Figure 5. The sequential steps for generation of C. glabrata gene deletion cassettes 
 
(A): Fusion PCR using the dominant selectable marker NAT1 was applied to generate gene 
deletion cassettes. The 5’ and 3’ flanking sequences of target genes were integrated in 
oligonucleotides to amplify the marker fragment and to add overlap sequences. (B): Gene 
disruption by replacement of the target gene based on homologous recombination. C. glabrata 
strain Δhtl was transformed by an electroporation method. (C): Verification of correct integration 
of the deletion cassette by colony PCR (forward primer outside flanking region and reverse 
primer inside marker) checking both junctions. Loss-of-gene PCR (internal primer pair) was 
used to confirm that the coding sequences has not reintegrated in the genome. Reintegration, 
indicating that the CDS remained in the genome, gave a 500 bp PCR product. Figure taken from 
(Schwarzmüller, T., 2009).  
 
2.10 Generation of revertants and complemented strains in C. glabrata 
 
 The set of full revertants (Δpst1:CgPST1 and Δecm33:CgECM33), incompleted 
revertants (Δpst1/Δecm33:CgPST1 and Δpst1/Δecm33:CgECM33) and complemented strains 
(Δecm33:truncated CgECM33, Δecm33:CgSPS2, Δecm33:CgSPS22, Δecm33:CgPST1, 
Δecm33:CaECM33 and Δecm33:ScECM33) were generated by using the target gene cloned to 




centromere (CEN), a leucine selectable marker of C. glabrata and a PGK1 (3-phosphoglycerate 
kinase 1) promotor of S. cerevisiae (ScPGK1) as shown in Figure 6. This system can restore gene 
expression in the generated knock out strains (Ma, B., Pan, S. J. et al., 2007; Schwarzmüller, T., 
2009). 
 All of the inserted fragments were amplified with specific primers including adaptors for 
restriction enzyme sites from CBS138/ATCC2001 genomic DNA. A 50 µl reaction (5 µl of 10x 
KOD Taq buffer, 5 µl of 2 mM dNTPs, 3 µl of 25 MgCl2, 1 µl of 20 µM each primer, 1 µl of 
KOD Taq-Polymerase (1U/µl; Novagen, Darmstadt, Germany), and 2 µl of genomic DNA (50 
ng/µl)) was subjected to cycling (95°C for 5 minutes, 35 cycles of 95°C for 30 seconds, XX°C 
(see annealing temperature in Table 9) for 30 seconds, 70°C for 30 seconds, finally 5 minutes at 
70°C in a thermocycler machine. The size of the inserted PCR products are shown in Table 9. 
 The pBM51-Leu and the inserted fragments were digested with a restriction enzyme. 
After digestion, the fragments and linearized pBM51-Leu plasmid were purified by using 
QIAquick Gel Extraction Kit (Qiagen). The ligation between the fragments and linearized 
pBM51-Leu plasmid were linked by using T4 DNA ligase (Thermo Scientific, MA, USA) as 
follows: linear vector 50 ng, inserted DNA fragment 250 ng, 2 µl of 10X T4 DNA ligase buffer 
and 1 µl of T4 DNA ligase (1U/µl). The mixtures were incubated at 25°C for 1 hour and kept in 
4°C for overnight. Five µl of the mixture was used for transformation in the competent DH5α E. 
coli using a heat shock transformation protocol (see the detail protocol in 2.10.1 and 2.10.2). The 
transformant DH5α E. coli was selected by using ampicillin drug resistance. 
 The positive DH5α clones were verified with two approaches as restriction enzyme 
digestion and DNA sequencing.  
 Plasmids from pBM51-Leu no. P7-P13 were extracted and used to transform C. glabrata 
by electroporation (see the detail protocol in 2.10.3 and 2.10.4). C. glabrata transformats were 
























Figure 6. Map of  pBM51-Leu  
 
pBM51-Leu map was drawn from online program PlasMapper Version 2.0 
(http://wishart.biology.ualberta.ca/PlasMapper/index.html). The pBM51-Leu can be replicated in 
E. coli using pBR322 origin of replication and expressed in S. cerevisiae and C. glabrata using 
strong promotor of S. cerevisiae. The pBM51-Leu’s multiple cloning site contains the following 
restriction sites: XhoI, AccI, EcoRV, XmaI, SmaI, and BamHI. The marker for selection in E. coli 
is ampicillin resistant and in yeast cell is leucine production.  
 
 
Table 9. Generation of revertants and complemented strains in C. glabrata 
 
Gene Size Primer code Annealing  temp. Restriction 
  (bp)   (
o
C)    enzyme 
CgECM33 1266 31 and 32 55    XhoI/BamHI 
CgPST1  1290 33 and 34 55   XhoI/BamHI 
truncated CgECM33 1185 31 and 75 55   XhoI/BamHI 
CgSPS2 1251 71.2 and 72 58   XhoI/BamHI 
CgSPS22 1377 69.2 and 70 58   SalI/BamHI 
CaECM33 1272 57 and 58 60   XhoI/BamHI 








2.10.1 Preparation of competent E. coli  
 
 A single colony of E. coli was grown in 5 ml LB in glass tube at 37°C for overnight with 
shaking. One ml of overnight culture was inoculated into 100 ml LB in a 250 ml flask and 
incubated at 37°C for 1.5-3 hours until an OD600 of 0.5. These cells were put on ice for 15 
minutes and the cells were collected by centrifugation for 3 minutes at 1,942 x g (3,000 rpm). 
The cell pellet was treated with cold 0.1 M CaCl2, incubated on ice for 20 minutes and 
centrifuged to keep the cell pellet. The cell pellet was resuspended with 2 ml cold 0.1 M CaCl2 in 
20% glycerol and aliquots of 100 µl competent cells were stored at -80°C (Sambrook, J., Russell, 
D.W., 2001). 
 
2.10.2 Transformation of E. coli 
 
 Fifty ng of circular plasmid was added into 100 µl of competent E.coli suspension and 
incubated on ice for 30 minutes. Then a heat shock was applied to the cells for 2 minutes at 42°C 
in a water bath before the cells were put back on ice. 500 ml of LB was added to the tube and 
incubated at 37°C for an hour and then plated on LB agar with selective antibiotic drug 
(Sambrook, J., Russell, D.W., 2001).  
 
2.10.3 Preparation of competent yeast cell 
 
 A combination of procedures modified from three protocols was used to prepare the 
competent C. glabrata and P. pastoris cells (Wu, S. and Letchworth, G. J., 2004; Lin-Cereghino, 
J., Wong, W. W. et al., 2005; Gietz, R. D. and Schiestl, R. H., 2007). A single colony of yeast 
was grown overnight in 5 ml YPD in a glass tube at 30°C with shaking.  One ml of an overnight 
culture was inoculated into 100 ml YPD in 250 ml flask and incubated additionally at 30°C for 
3-5 hours until an OD600 of 0.8 – 1.0 was reached. The cells were put on ice for 15 minutes and 
harvested by centrifugation for 3 minutes at 486 x g (1,500 rpm). The cell pellet was treated with 
10 ml cold transformation buffer (7.9 ml of TEDS, 2 ml of 500 mM, and 100 µl of 1M 




The cell pellet was washed with 10 ml cold 1 M Sorbitol and resuspended with 2 ml cold 1 M 
Sorbitol. Aliquots of 100 µl yeast competent cells were stored at -80°C 
  
2.10.4 Electroporation of yeast  
 
 5 µl (50 – 100 ng) of PmeI linearized plasmid in case of P. pastoris or circular plasmid in 
case of C. glabrata and 100 µl of competent yeast cells was mixed together and loaded into a 1 
mm gap electroporation cuvette (PeqLab Biotechnologie GmbH, Erlangen, Germany). The 
cuvette was incubated on ice for 5 minutes and was electroporated (parameters: charging voltage 
1,500 V, resistance 200 Ω and capacitance 25 µF). Immediately after electroporation, one ml 
cold 1 M sorbitol was added into cuvette and incubated in 30°C for 1 hour, and then plated on 
minimal media (Lin-Cereghino, J., Wong, W. W. et al., 2005). 
 
2.11 Reverse transcription real-time PCR 
 
 The total RNA was isolated using the RNeasy Mini Kit (Qiagen) from cells that were 
isolated from mid log-phase (OD600 of 0.8 – 1.2). The cells were broken using a mechanical 
disruption protocol with a Fast Prep 120 machine (RNeasy Mini Handbook page 49 -51) and the 
RNA concentration was measured using a Nanodrop spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, Germany) (Qiagen, 2006; Bader, O., Schwarz, A. et al., 2012) 
 One µg of total RNA was treated with DNase I (Fermentas) to eliminate genomic DNA 
and the reaction was stopped by EDTA solution. The pure RNA was reverse transcribed to 
complementary DNA (cDNA) by using First Strand cDNA Synthesis Kit with the oligo (dT) 18 
primer (Fermentas, 2009). 
 LightCycler
®
 Real-time PCR from Roche system was used for measurement of the level 
of gene expression. The conditions for a 20 µl reaction were as follows: 4 µl of Master mix, 1 µl 
of 20 µM each primer, and 2 µl of cDNA (20 ng/µl); 95°C for 10 minutes, 45 cycles of 95°C for 
10 seconds, 50°C for 10 seconds, 72°C for 10 seconds (Roche, 2007). The value of gene 





2.12 Growth assay 
 
 C. glabrata, C. albicans and S. cerevisiae cells were grown at 37°C for overnight in a 
shaking incubator. Cells from the overnight culture were harvested by centrifugastion, washed 
with ddH2O and adjusted to a density of 0.5 McFarland (5X10
6
 cells/ml) in 0.85% NaCl. The 
adjusted cell suspension was diluted 10-folds (1 ml cell suspension in 9 ml 0.85% NaCl). 100 µl 
of the diluted cell suspension was added into 96 well plates containing 2-fold concentrated 
RPMI1640 or YPD. For each strain, growth of three yeast suspensions were monitored at 30°C 
and 37°C by measuring the OD630 every 3 hours for 36 hours. 
 
2.13 Susceptibility testing to cell perturbing agents  
 
2.13.1 Agar drop dilution assay 
 
 Susceptibility testing to cell perturbing agents (Caffeine, Calcofluor white, and Congo 
red) was performed by agar drop dilution. To prepare the inoculum, yeast cells from agar plates 
were added to sterile 0.85% NaCl to a density of 0.5 McFarland (5×10
6
 cells/ml), diluted 10-fold 
in sterile 0.85% NaCl. Five µl of the diluted cell suspension was dropped onto agar plate 
containing cell perturbing agents. The plates were incubated at 30°C for 24 hours in case of C. 
glabrata and 48 hours in case of C. albicans and S. cerevisiae 
 
2.13.2 Broth micro-dilution assay 
 
 Susceptibility testing to cell wall perturbing agents (Calcofluor white, Congo red, Sodium 
dodecyl sulfate (SDS), Hygromycin B, Brefeldin A, Nikkomycin Z, and Lufenuron) was 
performed by broth micro-dilution. To prepare the inoculum, cells from agar plates were added 
to 0.85% NaCl to a density of 0.5 McFarland (5×10
6
 cells/ml), diluted 10-fold in 0.85% NaCl 
and 100 µl of the cell suspension was added to an equal volume of RPMI1640 containing the cell 
wall perturbing agent. 96 well plates with two-fold serial dilutions of cell wall perturbing agents 
were incubated at 37°C for 24 hours for C. glabrata and for 48 hours for S. cerevisiae and C. 




Technologies GmbH, Denkendorf, Germany). The minimum inhibitory concentration (MIC) 50 
and MIC90 were calculated from the value of absorbance 630 in analogy to the EUCAST 
methodology (EUCAST, 2008). 
 
2.14 Alcian blue binding assay 
 Alcian blue is a positively charged, blue colored dye, which binds to negative charges on 
the cell wall surface. The Alcian blue binding assay was adapted from two previous publications 
(Odani, T., Shimma, Y. et al., 1996; Hobson, R. P., Munro, C. A. et al., 2004). The overnight 
culture of yeast cells in YPD were adjusted to an OD600 of 1 in sterile PBS and centrifuged to 
collect the cells. The cell pellets were suspended in 1 ml of 30 μg/ml Alcian Blue in 0.02 M HCl 
(pH 3.0), incubated at room temperature for 10 minutes, and pelleted by centrifugation. 100 μl of 
supernatant was transferred into 96 well plates to measure the absorbance 630 nm by using a 
spectrophotometer. Alcian blue concentrations were determined by reference to a standard curve. 
Alcian Blue binding was calculated according to the formula: x = (u–v) ÷n  where x = Alcian 
blue binding, u = original Alcian blue concentration (μg/ml), v = final Alcian blue concentration 
(μg/ml), and n = amount of yeast cells in OD600.  
2.15 Flow cytometry measurement 
 
2.15.1 Glucan staining assay 
 
 Congo red was used to stain the glucan of the yeast cell wall. Cells from 1 ml of an 
overnight culture were harvested and washed twice with PBS. Cells were resuspended in 1 ml of 
1 M NaOH, boiled at 95°C for 5 minutes, washed again twice with PBS and incubated for 30 
minutes at room temperature in 300 μl Congo Red staining solution (200 mg/ml). After washing, 
stained cells were resuspended in 500 μl of water (Bader, O., Schwarz, A. et al., 2012). 
 
2.15.2 Chitin staining assay 
 
 Wheat-germ agglutinin (WGA–Alexafluor 647 conjugate (Invitrogen, OR, USA) was 




harvested and washed twice with PBS. Cells were resuspended in 1 ml of 1 M HCl, boiled at 
95°C for 5 minutes and then washed again twice with PBS. Cells were resuspended in 300 μl 
WGA staining solution (50 μg/ml), incubated for 30 minutes at room temperature and washed 
again twice. Stained cells were resuspended in 500 μl water (Bader, O., Schwarz, A. et al., 2012). 
 After staining, flow cytometric analyses were performed with a FACS Calibur flow 
cytometer using Cell QuestPro software (BD-Biosciences, NJ, USA). All values were calculated 
as the mean average fluorescence intensity of 12,000 events in three independent experiments 
(Bader, O., Schwarz, A. et al., 2012). 
 
2.16 Biofilm properties determination 
 
2.16.1 Hydrophobicity assay 
 
 The overnight culture of yeast cells in YPD were washed with ddH2O and adjusted to 
OD600 of 1 in sterile water. Two ml of cell suspensions were mixed with 2 ml Octane in glass 
tube with rubber cover and rigourously vortexed for 30 seconds. After the separation of the two 
layers, one ml of the bottom aqueous phase was taken to measure the OD600 by using 
spectrophotometer (de Groot, P. W., Kraneveld, E. A. et al., 2008). Hydrophobicity was 
calculated as the percentage of cells removed from the aqueous phase. 
 
2.16.2 Polystyrene adhesion assay 
 
 Cells were grown in YPD for 24 hours, after that the OD600 was adjusted to 2, and 50 µl 
of these cell suspensions were transferred into 150 µl fresh YPD medium in polystyrene 96-wells 
plates (Greiner bio-one). After 24 hours of incubation at 37
o
C, non-adherent cells were washed 
out with sterile water and the adherent cells were stained with 0.1% Crystal violet for 5 minutes. 
Excess Crystal violet was washed away and the cells were lysed with a solution containing 50% 
ethanol and 1% SDS. The amount of  adherent cells was determined by measuring crystal violet 





2.16.3 Silicone adhesion assay 
 
 1x1 cm. of silicone pieces (AMT Aromando, Duesseldorf, Germany) were incubated for 
24 hours at 37
o
C in 12-wells plates containing 2 ml YPD inoculated at a cell density of 0.08 
McFarland with the C.glabrata strains. To remove unbound cells by aspiration, silicone pieces 
were transferred into fresh 12-wells plates containing 1 ml PBS. Bound cells were scraped off, 
resuspended in 1.2 ml PBS, and quantified by measuring the OD600 (Bader, O., Schwarz, A. et 
al., 2012). 
 
2.17 Protein expression in P. pastoris 
 
 Ecm33 and Pst1 protein expression in Pichia pastoris was performed using the 
EasySelectTM Pichia Expression Kit (Invitrogen, CA, USA). Both proteins were expressed 
without the C-terminal signal peptides and ω-sites of the N-terminal regions. 
 The inserted fragments of ECM33 and PST1 were amplified from C. glabrata 
CBS138/ATCC2001 genomic DNA with specific primers including adaptors for restriction 
enzyme sites. A 50 µl reaction (5 µl of 10x KOD Taq buffer, 5 µl of 2 mM dNTPs, 3 µl of 25 
MgCl2, 1 µl of 20 µM each primer, 1 µl of KOD Taq-Polymerase (1U/µl; Novagen), and 2 µl of 
genomic DNA (50 ng/ µl)) was subjected to cycling (95°C for 5 minutes, 35 cycles 95°C for 30 
seconds, 58°C for 30 seconds, 70°C for 30 seconds, finally 5 minutes at 70°C) in a thermocycler 
machine. The expected PCR product size of each gene is shown in Table 10. The PCR product of 
target gene will be inserted at multiple cloning site of pPICZα vector as shown in Figure 7. 
 The pPICZα and the inserted fragments were digested with restriction enzyme (EcoRI 
and KpnI for ECM33 and EcoRI and XbaI for PST1) and the modified fragments and pPICZα 
linearlized plasmid purified using the QIAquick Gel Extraction Kit (Qiagen). The ligation of the 
modified fragments and pBM51 linearlized plasmid were ligated by using T4 DNA ligase 
(Thermo Scientific) as follows: linear vector 50 ng, inserted DNA 250 ng, 2 µl of 10X T4 DNA 
ligase buffer and 1 µl of T4 DNA ligase (1U/µl of). The mixtures were incubated at 25°C for 1 
hour and kept in 4°C for overnight. A 5 µl of the mixture was used for transformation in the 




2.10.1 and 2.10.2). The transformant DH5α E. coli was selected by using Zeocin
TM
 (Invitrogen, 
CA, USA) drug resistance. 
 Positive DH5α clones were verified by restriction enzyme double digestion and DNA 
sequencing. The pure recombinant pPICZα no. P4 and P5 were extracted and used to transform 
methylotrophic P. pastoris by electroporation (see the detail protocol in 2.10.3 and 2.10.4). The 
transformant P. pastoris was selected by using YPD agar containing Zeocin
TM
. The recombinant 
P. pastoris can grow in this selective YPD agar because it contains Zeocin resistant gene.   
 
2.17.1 Methanol induced Ecm33 and Pst1 protein expression   
 
 ECM33 and PST1 genes were transformed to the P. pastoris strain X33 (wid-type) and 
GS115 (his4). For expression, a representative single colony of each of the four recombinant 
strains  (GS115:CgECM33, GS115:CgPST1, X33:CgECM33 and X33:CgPST1) was grown in 25 
ml BMGH (buffered minimal glycerol histidine) in a 250 ml flask and incubated at 30°C for 
overnight that these cells will be in log-phase growth. These cells were harvested by 
centrifugation, resuspended and adjusted to an OD600 of 1 in 100 ml BMMH (buffered minimal 
methanol histidine) media in 500 ml flask.  Then, the cell suspensions were incubated at 30°C in 
shaking incubator 250 rpm for induction of ECM33 and PST1 expression. 
 One ml of cell suspensions were collected at 24, 48, 72, 96, and 120 hours to determine 
the time points that express the highest amounts of proteins in the four recombinant strains by 
using SDS-PAGE (Invitrogen, 2009). 
 
2.17.2 SDS-Polyacrylamide gel electrophoresis 
 
 All components of separating gel were mixed and pipetted into assembled gel plates of a 
BioRad Mini Protean II system. Then, 100 µl of butanol was added onto the top of gel to make a 
straight top of separating gel and the gel allowed to polymerize. The gel was cleaned by 
removing butanol and washing with water. All components of collective gel were mixed and 
pipetted onto the separating gel and that the comb was put into the gel and the gel allowed to 
polymerize (SDS-PAGE gel preparation is shown in Table 11). SDS-PAGE gels were stored at 
4
o




 The protein solution was mixed with 5X loading buffer and boiled at 95°C for 10 minutes 
then loaded onto the SDS-PAGE gel.  Coomassie blue was used to stain the proteins in the SDS-
PAGE gels. 
 
Table 10. Generation of recombinant ECM33 and PST1 plasmids for protein expression 
 
Gene Size Primer code Annealing  temp. Restriction 
  (bp)   (
o
C)    enzyme 





3 and 7 






¹: protein expression in P. pastoris. 




Table 11. SDS-PAGE gel preparation 
 
   Collective gel Separating gel 
  5% 10% 12% 15% 
Water 1.4 ml 2.95 ml 2.45 ml 1.7  ml 
Buffer 630 µl 1.9 ml 1.9 ml 1.9 ml 
Acrylamide solution
a
 415 µl 2.5 ml 3 ml 3.75 ml 
10% SDS 25 µl 75 µl 75 µl 75 µl 
10% APS 25 µl 75 µl 75 µl 75 µl 
TEMED 2.5 µl 3 µl 3 µl 3 µl 
 
a








Figure 7. Map of  pPICZα 
 
pPICα plasmid is 3.6 kilobases vector that used to express and secrete recombinant proteins in P. 
pastoris. Recombinant protein is expressed as fusions to an N-terminal peptide encoding the S. 
cerevisiae α-factor secretion signal. This plasmid allows high-level, methanol inducible 
expression of the gene of interest in P. pastoris. pPICα plasmid contains the following elements: 
AOX1 promoter for methanol-induced expression of the gene of interest, α-factor secretion 
signal for directing secreted recombinant protein expression, Zeocin resistance gene for 
selection, C-terminal peptide containing the c-myc epitope and a polyhistidine (6xHis) tag for 
detection and purification. Figure taken from (Invitrogen, 2009). 
 
2.18 Protein deglycosylation 
 
 N-glycosidase (Endo-α-N-Acetylgalactosaminidase; New England BioLabs Inc.) and O- 
glycosidase (PNGase F; New England BioLabs Inc.) were used to be a tool to eliminate N-
glycan and O-glycan, respectively. The mixture of substrate and glycosidase enzyme was 
incubated at 37
o







2.19 Protein expression in E. coli and Anti-Ecm33 antibody production 
  
2.19.1 Cloning of ECM33 gene in E. coli 
  
 F-LM-pQE and R-LM-pQE primers (Table 8) were used to amplify the ECM33 gene of 
C. glabrata without the signal peptide and the GPI-anchoring site. A 50 µl reaction (5 µl of 10x 
KOD Taq buffer, 5 µl of 2 mM dNTPs, 3 µl of 25 MgCl2, 1 µl of 20 µM each primer, 1 µl of 
KOD Taq-Polymerase (1U/µl; Novagen) and 2 µl of genomic DNA (50 ng/ µl)) was subjected to 
cycling (95°C for 5 minutes, 35 cycles of 95°C for 30 second, 58°C for 30 second, 70°C for 30 
second, finally 5 minutes at 70°C.) in a thermocycler machine. 
 The PCR product of ECM33 (product size 1,146 bp) was cloned into the pQE30 
expression vector (Figure 8) by using BamHI and PstI restriction enzymes as shown in Table 10. 
The recombinant plasmid pQE30:CgECM33 was transformed to the E. coli strain DH5α for 
plasmid multiplication and BL-21 for Ecm33 protein expression. Ampicillin resistance was used 
to select the positive clones (Qiagen, 2003). The detail of the ligation, E. coli competent 
preparation, and transformation were described in 2.10.1 and 2.10.2. 
 The positive DH5α clones were verified by using restriction enzyme double digestion and 
DNA sequencing.  
 
Figure 8. Map of pQE-30 
pQE-30 plasmid is 3.4 kilobases vector that used to express recombinant protein in E. coli. This 
vector contains the following elements: the phage T5 promoter transcription–translation system, 
two lac operator sequences, 6xHis-tag coding sequence, multiple cloning site, β-lactamase gene 




2.19.2 CgEcm33 protein expression in E. coli 
 
 A single colony of recombinant E. coli was grown in 20 ml of LB broth containing 100 
µg/ml ampicillin and 25 µg/ml of kanamycin at 37°C for overnight in shaker incubator at 250 
rpm. The overnight culture was diluted 50-folds (4 ml in 200 ml LB with antibiotics) and grown 
at 37°C with vigorous shaking until an OD600 of 0.6-0.8 was reached. IPTG (Roth) was added 
into the culture medium with a final concentration 1 mM and incubated for 4-5 hours. The 
Ecm33 expressing cells were harvested by centrifugation at 1,942 x g (3,000 rpm) for 10 minutes 
and frozen in -80°C (Qiagen, 2003). 
 
2.19.3 Ecm33 protein purification 
 
 The pellect from 50 ml culture was mixed with lysis solution for protein expression (5 ml 
of Bugbuster
®
 (Merck), 0.1 mg of lysozyme powder (Fluka), 5 µl of Benzouase (Novagen), and 
220 µl of protease inhibitor cocltail (Roche) and incubated for 40 minutes at room temperature. 
After incubation, the cloudy solution was centrifuged to collect the pellet and dissolved with 8M 
urea solution at 40°C for 20 minutes. The protein solution was centrifuged at 1,942 x g (3,000 
rpm) to remove the cell debris and the supernatant was kept at -20
o
C. 
 His-Tag affinity chromatography was used to purify the Ecm33 protein. Two ml of Ni-
NTA resin solution (Qiagen) was added into a column. Columns were equilibrated with 5 CV 
wash buffer. The lysate was loaded into column and the flow-through was collected in 3 portions 
of 1 ml. The target protein that bound to Ni-NTA resin was washed with 10 CV wash buffer and 
the flow-through was collected in 5 portions of 1 ml. The target protein was eluted with wash 
buffer containing 250 mM imidazole, and collected in 5 portions of 1 ml. All samples were 
analyzed by using SDS-PAGE (see the detail in 2.17.2). 
 




(Merck) was used to measure the concentration of protein in a solution 
according to the manufacturer’s instructions. 0.05 – 0.5 mg/ml of Bovine serum albumin (BSA) 






, incubated for 2 minutes at room temperature and measured absorbance at 570 
nm. 
 
2.19.5 Western blotting analysis 
  
 Protein from SDS-PAGE was transferred onto a PVDF membrane by using wet blotting. 
After blotting, the PVDF membrane was blocked with 20 ml of 5% (w/v) skim milk for 1 hour 
and then washed twice with 20 ml of PBST. The PVDF membrane was incubated with the 
primary antibody at 4°C for overnight and then washed three times with 20 ml of PBST. The 
secondary antibody was added and incubated at room temperature for 2 hours and the membrane 
washed three times with 20 ml of PBST. ECLTM Western blotting Detection Reagent (GE 
Healthcare, Buckinghamshire, UK) was used in the detection step and the image was taken with 
the Fujifilm LAS 4000 system. 
 
2.19.6 Anti-Ecm33 antibody production 
  
 The immunisation procedure was performed by Eurogentec, Liège, Belgium. Before start 
the immunization program, serum of non-immunized rabbits were tested for Ecm33 antibodies to 
circumvent cross-reactions. 
 A polyclonal anti-Ecm33 serum was produced with the “anti-protein 87-days polyclonal 
package” of Eurogentec. Briefly, 100 µg purified CgEcm33 protein antigen was immunized in a 
rabbit on day 0, 14, 28, and 56. Serum was taken from the rabbits at day 0 (pre-immune serum) 
and day 38, 66, and 87 after immunization as shown in Figure 9. The immunized rabbit serum 




Figure 9. The time line of the anti-Ecm33 antibody production 






2.20 Cell wall protein release assay 
 
 An overnight culture of yeast cells in YPD was washed and adjusted to an OD600 of 0.1 
in 100 ml of minimum medium (MM). The cell suspension was incubated at 37
o
C for 24 hours in 
shaker incubation at 250 rpm. The supernatant was collected by two times of centrifugation at 
486 x g (1,500 rpm) for 10 minutes to remove the cells. To concentrate the supernatant, a 15 ml 
spin column with a pore size of 10 kDa (Sartorius, Göttingen) was used to reduce the volume of 
supernatant 50-folds. The protein concentration in the supernatant was determined by using 
BIOQUANT
® 
(see the detail in 2.19.4). Western blot analyses were performed to check for 
reactivity of released material with rabbit anti-Cwp1 or rabbit anti-1,6-β-glucan. 
 
2.21 Cell wall extraction 
 
 Cell wall extraction was performed as described de Groot et al (de Groot, P. W., de Boer, 
A. D. et al., 2004; de Groot, P. W., Kraneveld, E. A. et al., 2008). Briefly, yeast cells were fully 
disintegrated with 0.25 to 0.50 mm. glass beads (Emergo BV) in the presence of a protease 
inhibitor cocktail (Sigma) using a Bio-Savant FastPrep 120 machine (Qbiogene). To remove 
non-covalently linked proteins and intracellular contaminants, isolated cell walls were washed 
extensively with 1 M NaCl and twice extracted with 2% SDS, 150 mM NaCl, 100mM Na-
EDTA, 100 mM β-mercaptoethanol, and 50 mM Tris-HCl, pH 7.8, for 5 minutes at 100°C. SDS-
treated walls were washed with water until no foaming was observed anymore. The extracted 
cell walls (ECWs) were freeze-dried with lyophilization and stored at 20°C until further use. 
 
2.22 Binding assay 
 
 20 µl (20 mg/ml)  of extracted cell walls (ECWs) were incubated with 20 µl of ELISA 
blocking solution for 1 hour at 37
o
C and washed twice with 1 ml of PBS. The blocked ECWs 
were incubated with 10 µl (250 µg/ml) of Ecm33 or Pst1 protein for 1 hour at 37
o
C and washed 
twice with 1 ml of PBS to remove unbound protein. The pellets were resuspended with 10 µl 
steriled water and 4 µl of 5X loading buffer. Potential binding between ECWs and recombinant 




2.23 Statistical analyses 
 
 Three independent experiments were done in all yeast strains. Statistical significance for 
phenotypic tests was calculated using Student’s t-test with Microsoft Excel. p-value < 0.05 were 













3.1 In silico analysis of the Ecm33 family 
 
 In silico analyses showed that the Ecm33, Pst1, Sps2 and Sps22 proteins of C. glabrata 
consist of a signal peptide, and a short serine/threonine rich region, preceeding an omega site for 
GPI anchor addition at the C-terminus. Framing the central part of the mature protein four 
conserved cysteine sites can be found, potentially adding to the protein stability by formation of 
disulphide bonds as shown in Figure 10 and Figure 11. 
 
 
Figure 10. Ecm33 protein family structure of C. glabrata 
 
Signal peptides were predicted by using SignalP. Omega sites for GPI anchor attachment were 
predicted using the big-PI Predictor server. All proteins feature a serine/threonine rich region and 
four conserved cysteine residues, potentially involved in the formation of disulfide bonds. 





Figure 11. Sequence alignment of mature proteins of the Ecm33 families in C. glabrata, C. 
albicans and S. cerevisiae.  
 
Shaded regions; green: conserved cysteins, red: fully conserved residues, potentially contributing 
towards function, blue: S/T-rich region. Signal peptides for ER-entry and GPI-modification were 




 The relatedness of the different proteins of the Ecm33 families of C. glabrata, C. 
albicans, and S. cerevisiae were analysed by creation of a protein sequence alignment and a 
phylogenetic tree derived thereof.  
 Next to the four conserved cysteines already described above for the four proteins from 
C. glabrata, three additional highly conserved regions can be observed in the mature protein 
sequences: at positions 206-208 an SDT motif, at postions 230-232 an NNN motif and last at 
positions 375-380 a LK.V.G-motif as shown in Figure 11. Other than that, several conserved 
proline and glycine residues are found. 
 Amino acid identity matrices (Table 12 and Table 13) show that C. glabrata Ecm33 
shares 67% homology with the Ecm33 protein of S. cerevisiae and 73% in the Pst1 protein. In 
contrast, the homology to the respective proteins in C. albicans is only 30% and 33%, 
respectively. Although Sps2 and Sps22 are grouped in the same family, the homology with the 
Ecm33 protein is only approximately 30% in all three organisms. Phylogenic clustering (Figure 
12) and calculation of amino acid identity matrices indicates that the members of the Ecm33 
protein family in can be divided into two groups; (i) Ecm33 and Pst1, and (ii) Sps2 and Sps22. 
An ortholog of Sps22 is not found in C. albicans. 
 
 
Figure 12. The Ecm33 family phylogeny of C. glabrata, C. albicans and S. cerevisiae. 
 
Phylogenetic clustering of eleven protein sequences of the Ecm33 family in C. glabrata, C. 
albicans and S. cerevisiae shows separation into two distinct subgroups. An ortholog of the  




Table 12. Identity matrix of the entire protein in the Ecm33 family of C. glabrata, C. 




ID: identity   
 
 
Table 13. Identity matrix of Ecm33 family effector domains only of C. glabrata, C. albicans 








3.2 Confirmation of knock out strains 
 
 Single deletion mutants of PST1 (Δpst1) and ECM33 (Δecm33) and a double mutant 
(Δpst1/Δecm33) in C. glabrata were provided by Tobias Schwarzmüller (Univerity of Vienna, 
Cg-Ecm33 Cg-Pst1 Cg-Sps2 Cg-Sps22 Ca-Ecm33 Ca-Pst1 Ca-Sps2 Sc-Ecm33 Sc-Pst1  Sc-Sps2 Sc-Sps22
Cg-Ecm33 ID 0.62 0.196 0.213 0.308 0.317 0.213 0.67 0.524 0.24 0.216
Cg-Pst1 0.62 ID 0.214 0.213 0.327 0.315 0.203 0.561 0.556 0.235 0.225
Cg-Sps2 0.196 0.214 ID 0.313 0.177 0.213 0.21 0.197 0.2 0.324 0.355
Cg-Sps22 0.213 0.213 0.313 ID 0.201 0.193 0.224 0.2 0.196 0.304 0.347
Ca-Ecm33 0.308 0.327 0.177 0.201 ID 0.366 0.174 0.331 0.31 0.205 0.19
Ca-Pst1 0.317 0.315 0.213 0.193 0.366 ID 0.213 0.315 0.283 0.215 0.205
Ca-Sps2 0.213 0.203 0.21 0.224 0.174 0.213 ID 0.213 0.24 0.237 0.253
Sc-Ecm33 0.67 0.561 0.197 0.2 0.331 0.315 0.213 ID 0.572 0.252 0.238
Sc-Pst1  0.524 0.556 0.2 0.196 0.31 0.283 0.24 0.572 ID 0.233 0.229
Sc-Sps2 0.24 0.235 0.324 0.304 0.205 0.215 0.237 0.252 0.233 ID 0.4
Sc-Sps22 0.216 0.225 0.355 0.347 0.19 0.205 0.253 0.238 0.229 0.4 ID
Cg-Ecm33 Cg-Pst1 Cg-Sps2 Cg-Sps22 Ca-Ecm33 Ca-Pst1 Ca-Sps2 Sc-Ecm33 Sc-Pst1  Sc-Sps2 Sc-Sps22
Cg-Ecm33 ID 0.674 0.278 0.271 0.334 0.351 0.306 0.73 0.613 0.339 0.293
Cg-Pst1 0.674 ID 0.297 0.271 0.362 0.358 0.279 0.616 0.647 0.328 0.303
Cg-Sps2 0.278 0.297 ID 0.371 0.225 0.273 0.303 0.272 0.287 0.445 0.453
Cg-Sps22 0.271 0.271 0.371 ID 0.24 0.243 0.334 0.256 0.265 0.425 0.449
Ca-Ecm33 0.334 0.362 0.225 0.24 ID 0.37 0.231 0.325 0.352 0.268 0.237
Ca-Pst1 0.351 0.358 0.273 0.243 0.37 ID 0.296 0.342 0.333 0.304 0.267
Ca-Sps2 0.306 0.279 0.303 0.334 0.231 0.296 ID 0.293 0.327 0.343 0.366
Sc-Ecm33 0.73 0.616 0.272 0.256 0.325 0.342 0.293 ID 0.622 0.342 0.302
Sc-Pst1  0.613 0.647 0.287 0.265 0.352 0.333 0.327 0.622 ID 0.324 0.305
Sc-Sps2 0.339 0.328 0.445 0.425 0.268 0.304 0.343 0.342 0.324 ID 0.506




Austria). There, the strains were generated by using a fusion PCR to construct a recombinant 
pTS50 plasmid that was used to transformed the parental strain (wild-type auxotroph Δhtl), with 
selection for NAT (nourseothricin-resistance gene) transformants on YPD medium plates 
(Schwarzmüller, T., 2009). 
 To comfirm the gene deletion status of the mutants received, the Δpst1 strain was 
analysed by using two PCR reactions: the first analysis using primers 13 F-MuE-Cont and 11 
hk2 to verify integration of NAT gene at the 5’ site and the second analysis using the primers 14 
R-MuE-Cont and 12 hk3 to confirm integration of the knock out cassette at the 3’ end. Similarly, 
the deletion strain Δecm33 was tested with primer pair 15 F-MuM-Cont and 11 hk2 for 5’ site 
and primer pair 16 R-MuM-Cont and 12 hk3 for the 3’ end. In strain Δpst1/Δecm33, the primer 
pair 13 F-MuE-Cont and 11 hk2 were used to confirm PST1 gene deletion and primer 16 R-
MuM-Cont and 12 hk3 for ECM33 gene deletion. The PCR product size observed was 
approximately 800 bp for all reactions as shown in Figure 13 as expected for positive reactions. 
 
Figure 13. Confirmation of knock out strains by PCR 
 
Lane 1: DNA Marker, lane 2: Δpst1 DNA with primer no. 13 and 11, lane 3: Δpst1 DNA with 
primer no. 14 and 12, lane 4: Δecm33DNA with primer no. 15 and 11, lane 5: Δecm33DNA with 
primer no. 16 and 12, lane 6: Δpst1:Δecm33 DNA with primer no. 13 and 11, and lane 7: 
Δpst1:Δecm33 DNA with primer no. 16 and 12 
 
 As a further control, reverse transcription real-time PCR was performed to analyze gene 
expression in the generated mutant strains Δpst1, Δecm33 and Δpst1/Δecm33 in comparison to 




used for normalization of expression levels. The results confirmed that there was no expression 
of the deleted genes in the generated knock out strains. Furthermore, no compensatory up-
regulation of other family member genes was observed in the gene deletion mutants (Figure 14). 
 
 
Figure 14. Reverse transcription real-time PCR to analyse the expression levels of the 
ECM33 gene family in the generated mutants 
 
Reverse transcription real-time PCR analyses of ECM33 gene family (average of three 
independent experiments). The wild-type auxotroph strain Δhtl expressed all genes that was 
tested and the generated mutant strains did not expressed the gene that was deleted. There was no 
compensatory up-regulation of SPS2/22 or PST1/ECM33 in the mutants. The housekeeping 
genes ACT and SLT were used for normalization. 
 
 3.3 Generation of revertants and complemented strains 
 
 All of the completed revertants (Δpst1:CgPST1 and Δecm33:CgECM33), incompleted 
revertants Δpst1/Δecm33:CgPST1 and Δpst1/Δecm33:CgECM33 and respective complemented 
strains (Δecm33:truncated CgECM33, Δecm33:CgSPS2, Δecm33:CgSPS22, Δecm33:CgPST1, 
Δecm33:CaECM33 and Δecm33:ScECM33) were generated by cloning the respective genes into 
expression plasmid pBM51 (Figure 6). Briefly, the inserted fragments were amplified with 




were verified with double restriction enzyme digestion as shown in Figure 16. The confirmed 
recombinant pBM51 plasmids were transformed into C. glabrata by electroporation. To verify 
the expression of revertant and complemented C. glabrata, a reverse transcription real-time PCR 
were performed for measurement of the level of target gene expression as shown in Figure 18. 
 All of the revertant strains expressed the inserted gene. The Δpst1:CgPST1 and 
Δpst1/Δecm33:CgPST1 could express PST1 in the same level as compared to the Δhtl 
auxotrophic wild-type strain. Δecm33:CgECM33 and Δpst1/Δecm33:CgECM33 expressed 
ECM33, but approximately 15% and 10% lower as compared to the Δhtl auxotrophic strain. As 
demonstrated before, there was no PST1 and ECM33 expression in the respective mutants when 
the gene was deleted (Figure 17).  
 In complemented strains, Δecm33:truncated CgECM33, Δecm33:CaECM33, and 
Δecm33:ScECM33 could express ECM33 at levels around 70%, 90%, and 90% of the Δhtl 
auxotrophic strain, respectively. The strains Δecm33:CgPST1, Δecm33:CgSPS2, and 
Δecm33:CgSPS22 contained two copies of PST1 and SPS2 and SPS22, respectively. However, 
there was only a low level of overexpression (~105%) of these genes in these strains, when 











Figure 15. PCR products for recombinant pBM51 construction 
 
PCR products of the interested genes were amplified from genomic DNA in case of C. glabrata 
and cDNA in case of C. albicans and S. cerevisiae with specific primers (Table 9). All lanes 
show a the expected  specific amplification product. Non-specific PCR products were not 
observed. Lanes 1,4,9: DNA marker, lane 2: CgECM33 , lane 3: CgPST1, lane 5: CgSPS22, lane 
6: CgSPS2, lane 7: empty, lane 8: truncated CgECM33, lane 10: CaECM33 and lane 11: 
ScECM33 












Figure 16. Enzyme digestion for verification of recombinant pBM51 plasmid 
 
The recombinant pBM51 plasmids were extracted from the positive E. coli clones. Verification 
of these recombinant plasmids were performed by using restriction enzyme digestion. All 
recombinant plasmids containing the inserted genes show two bands on agarose gel. An upper 
band is pBM51 fragment and a lower band is the inserted gene. Lane 1: pBM51:CgECM33, lane 
2: pBM51:CgPST1, lane 3: pBM51:CgSPS2, lane 4: pBM51:CgSPS22, lane 5,8,11: DNA 
marker, lane 6: BamHI digested pBM51:CgECM33, lane 7: two forms pBM51:truncated 
CgECM33 (upper is relaxed form and lower is supercoiled circular), lane 9: pBM51:truncated 




Figure 17. Reverse transcription real-time PCR for the measurement of PST1 and ECM33 
gene expression in revertant strains 
 
(A.): transcription levels of PST1; both PST1 revertants show PST1 gene expression as well as 
the Δhtl auxotrophic strains (B.): transcription levels of ECM33; both ECM33 revertants show 
expression of the ECM33 genes but not in the same level as the Δhtl auxotrophic strains. *: 
statistically significant differences (p< 0.05). Error bars represent the mean value calculated from 
triplicate experiments (±SD). 






Figure 18. Expression levels of the ECM33 gene family members in complemented strains 
 
Relative quantification of gene expression of ECM33 gene family. The complemented strains of 
the ECM33 genes from C. glabrata, C. albicans and S. cerevisiae show expression of the 
introduced genes. Introduction of additional copies of PST1, SPS2, and SPS22 in Δecm33 did not 
lead to significant up-regulation when compared to Δecm33. The housekeeping genes ACT and 
SLT were used for normalization. *: statistically significant differences (p< 0.05). Error bars 
represent the mean value for triplicate experiments (±SD). 
 
 
3.4 Growth rate determination 
  
 To asses whether deletion of any of the genes leads to growth defects and if in such cases 
the phenotype was recovered in reconstitutet strains, growth rates in YPD and RPMI 1640 media 
were determined at both 30°C and 37°C. Comparison of growth rates showed that all strains 
from C. albicans, S. cerevisiae, C. glabrata grew best in YPD at 37
o





 The C. albicans mutant strain Δecm33:Δecm33 showed delayed growth as compared to 
the auxotrophic wild-type strain (Caf2) and its reconstituted control 
(Δecm33:Δecm33:ECM33:ECM33) under all conditions tested as shown in Figure 19. 
 In S. cerevisiae, the growth rate of the auxotrophic wild-type strain BY4741 was similar 
to the Δpst1 mutant. Moreover, the growth rate of the deletion mutant Δecm33 (BY4741 genetic 
background) was similar to the mutant Δecm33 (FBEH041 genetic background) but both Δecm33 
strains grew slower when compared with the respective parental auxotrophic wild-type strains 
and the Δpst1 mutant. The Δpst1/Δecm33 strain grew significantly slower than both, the wild-
type and the single gene deletion mutants as shown in Figure 20. 
 In C. glabrata, the growth rate of wild-type strain CBS138/ATCC2001 was similar to the 
auxotrophic wild-type strain Δhtl and Δpst1 mutant. The Δecm33 mutant grew slower than the 
wild-type and the Δpst1 mutant. The Δpst1/Δecm33 mutant grew significantly slower than the 
wild-type, Δpst1, and Δecm33 as shown in Figure 21. 
 The growth rate of the revertants indicated that Δecm33:CgECM33, 
Δpst1/Δecm33:CgPST1, and Δpst1/Δecm33:CgECM33 grow slower than the auxotrophic wild-
type strain Δhtl and the Δpst1 mutamt, but faster than the Δecm33 and Δpst1/Δecm33 as shown in  
Figure 21. Gene reversion can therefore restore the growth rate from the mutants close to 
approximate levels of the parental strain, as shown in Figure 21 and Figure 22 A. 
 Complementations of CgECM33 with the ortholog from either S. cerevisiae or C. 
albicans rescued the growth defect in C. glabrata (Figure 23 B). However, addition of a second 
allele of either PST1, SPS2, or SPS22 under the ECM33 promotor does not rescue the ecm33 
growth defect (Figure 23 A). Neither does introduction of a truncated version of ECM33 without 
















Figure 19. Growth assays of C. albicans mutants 
 
(A.): YPD at 30
o
C, (B.): YPD at 37
o
C, (C.): RPMI 1640 at 30
o
C, and (D.): RPMI 1640 at 37
o
C. 
The cultures of C. albicans cells were grown in 96-well plates monitored for 36 hours and 
measured an optical density at 630 nm. The Δecm33:Δecm33 mutant has a slower growth as 
compared with Caf2 auxotrophic wild-type. The reduced growth rate of the mutant was restored 

















Figure 20. Growth assays of S. cerevisiae mutants 
 
(A.): YPD at 30
o
C, (B.): YPD at 37
o
C, (C.): RPMI 1640 at 30
o
C, and (D.): RPMI 1640 at 37
o
C. 
The cultures of S. cerevisiae cells were grown in 96-well plates, monitored for 36 hours and 
measured an optical density at 630 nm. The Δecm33 mutant has a slower growth as compared to 
the BY4741 auxotrophic wild-type and Δpst1 mutant. The Δpst1/Δecm33 double mutant has the 
slowest growth as compared to all other strains. Control strains with the re-introduced genes 
were not available. Two separate genetic backgrounds were used to construct single and double 


















Figure 21. Growth assays of C. glabrata mutants 
 
(A.): YPD at 30
o
C, (B.): YPD at 37
o
C, (C.): RPMI 1640 at 30
o
C, and (D.): RPMI 1640 at 37
o
C. 
The cultures of C. glabrata cells were grown in 96-well plates, monitored for 36 hours and 
measured an optical density at 630 nm. The Δecm33 mutant has a slower growth as compared to 
the wild-type and Δpst1 mutant. The Δpst1/Δecm33 mutant has the slowest growth as compared 







Figure 22. Growth curve of complementation experiments C. glabrata in YPD at 37
o
C 
C. glabrata strains were determined in 96-well plates, monitored for 36 hours and measured an 
optical density at 630 nm. Growth comparisons of (A.): strains complemented with C. glabrata 
ECM33, PST1, SPS2, and SPS22. (B.): complemented strains using C. albicans and S. cerevisiae 




3.5 Phenotypic analysis 
 
3.5.1 Measurement of cell wall strength 
 
 To measure the effect of the different gene deletions on cell wall strength, growth assays 
on solid media supplemented with different concentrations of known cell-wall perturbing agents 
were carried out. As a starting point, previously published concentrations for the respective 
strains from C. albicans (Martinez-Lopez, R., Monteoliva, L. et al., 2004) and S. cerevisiae 
(Pardo, M., Monteoliva, L. et al., 2004) were chosen.  
 In C. albicans, the phenotypic differences between the ∆ecm33 mutant and the 
auxotrophic wild-type strain (Caf2) when exposed to 5 mM Caffeine, 50 µg/ml Calcofluor white, 
and 200 µg/ml Congo red were seen (Figure 23 B). 
 Similarly, for S. cerevisiae the ∆pst1 mutant had no phenotypic difference compared to 
the the auxotrophic wild-type strain BY4741, but two independent ∆ecm33 mutants, showed a 
significantly decreased growth at concentrations of 10 mM Caffeine, 10 µg/ml Calcofluor white, 
and 50 µg/ml Congo red. The ∆pst1/∆ecm33 mutant also displayed a increased susceptibility in 
these assays (Figure 24 C). 
 However, there were no phenotypic differences among C. glabrata wild-type, 
auxotrophic wild-type, single mutants and double mutant when tested with 10 mM Caffeine, 500 
µg/ml Calcofluor white, and 500 µg/ml Congo red (Figure 23 A). Of note, these concentrations 
were several fold higher in C. glabrata than the concentrations necessary to assay the phenotypes 
in C. albicans and S. cerevisiae.  
 Therefore, additional liquid culture (broth microdilution) assays were performed to 
confirm these data. The minimum inhibitory concentration (MIC)50- and MIC90-values were 
used as the indicators for a quantitative evaluation in sensitivity testing.  
 When the wild-type strains of  C. glabrata, C. albicans and S. cerevisiae were compared 
in these assays, the CFW and Congo red MIC50- and MIC90-values were significantly higher in 
























Figure 23. Sensitivity testing of C. glabrata, C. albicans and S. cerevisiae to cell perturbing 
agents by using agar drop dilution assay 
 
(A): C. glabrata, (B): C. albicans, and  (C): S. cerevisiae. The ECM33 gene deletion of C. 
albicans and S. cerevisiae resulted in the expected susceptibility to cell wall perturbing agents 
((Martinez-Lopez, R., Monteoliva, L. et al., 2004; Pardo, M., Monteoliva, L. et al., 2004)); the 
Δecm33 mutant of C. albicans and the Δecm33 and Δpst/Δecm33 mutants of S. cerevisiae are 
susceptible to Caffeine, CFW, and Congo red as compared to wild-type auxotrophic strain. 













       YPD                  10mM Caffeine            500µg/ml CFW     500µg/ml  Congo red 

























Using liquid culture assays the C. glabrata Δecm33 mutant was moderately more 
sensitive to CFW and Congo red as compared to the wild-type strains. In the double mutant 
Δpst1/Δecm33, these phenotypes were strongly aggravated (Table 14). The broth microdilution 
assays confirmed that the complemented C. glabrata mutants regained their cell wall rigidity. 
For example, the MIC50 for CFW of the Δecm33 mutant is 250 µg/ml, but increases to 500 
µg/ml in the revertant Δecm33:CgECM33 and reaches the level of the wild-type and auxotrophic 
strain (Table 14). 
 In contrast, when CgPST1, CgSPS2 or CgSPS22 was introduced into the Δecm33 mutant 
(Δecm33:CgPST1, Δecm33:CgSPS2, and Δecm33:CgSPS22), the phenotype was not rescued, 
indicating that these homologs can not take over the function of ECM33 in C. glabrata (Table 
14). Furthermore, a truncated version of CgECM33 without the GPI anchor site was not able to 
restore the phenotypic defects of the Δecm33 mutant in C. glabrata. In all phenotypic assays, the 
Δecm33:truncated CgECM33 showed the same MIC50- and MIC90-values as compared to 
Δecm33 (Table 14). These phenotypic differences of the revertants (Δecm33:truncated CgECM33 
vs Δecm33:CgECM33) show that the GPI anchor site of the Ecm33 protein is necessary for 
native Ecm33 function. 
 Interestingly, the C. albicans and S. cerevisiae orthologs of CgECM33 (CaECM33 and 
ScECM33) were able to restore the phenotypes of CgΔecm33 and the revertants 
Δecm33:CaECM33 and Δecm33:ScECM33 display similar MIC50- and MIC90-values as the C. 
glabrata wild-type strain. 
 In C. albicans, the mutant strain Δecm33:Δecm33 was more sensitive to all cell 
perturbing agents when compared to the auxotrophic wild-type strain (except Lufenuron) and the 
revertant strains showed the same MIC50- and MIC90-values as the wild-type auxotrophic strain 
for all tested perturbants (Table 14). 
 In S. cerevisiae neither Brefeldin A, Nikkomycin Z nor Lufenuron did not inhibit the 
growth of the yeast cells in the tested concentration range. The two strains of Δecm33 mutants 
were more sensitive to CFW, Congo red, and Hygromycin B. With all cell perturbing agents, the 
∆pst1 mutant showed similar phenotypes as compared to the wild-type auxotroph (BY4741). 
However, the Δpst1/Δecm33 mutant was found to be four-times more sensitive when compared 





Table 14. Summary of results obtained by broth microdilution assay 
 
MIC50 and MIC90: the minimum inhibitory concentration 50 and 90%, NI: no-inhibition. 
Organisms Strains/Chemical agents
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
C. glabrata wild-type 500 NI NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆htl  (auxotroph) 500 NI NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆pst1 500 NI NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆pst1/∆ecm33 125 500 250 NI 0.00313 0.00625 50 100 NI NI NI NI NI NI
∆pst1:CgPST1 500 NI NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:CgECM33 500 1000 NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆pst1/∆ecm33:CgPST1 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆pst1/∆ecm33:CgECM33 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:truncated CgECM33 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:CgPST1 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:CgSPS2 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:CgSPS22 250 1000 500 NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:CaECM33 500 1000 NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
∆ecm33:ScECM33 500 1000 NI NI 0.00625 0.00625 100 200 NI NI NI NI NI NI
C. albicans Caf2  (auxotroph) 62.5 125 15.625 31.25 0.00625 0.00625 400 400 3.75 7.5 NI NI NI NI
∆ecm33:∆ecm33 31.25 62.5 7.81 7.81 0.00625 0.00625 50 100 1.875 3.75 8 NI NI NI
∆ecm33:∆ecm33:ECM33:ECM33 62.5 125 15.625 31.25 0.00625 0.00625 400 400 3.75 7.5 NI NI NI NI
S. cerevisiae BY4741 (auxotroph) 31.25 62.5 15.625 31.25 0.00625 0.00625 25 50 NI NI NI NI NI NI
∆pst1  (BY4741) 31.25 62.5 15.625 31.25 0.00625 0.00625 25 50 NI NI NI NI NI NI
∆ecm33 (BY4741) 15.625 31.25 7.81 15.625 0.00625 0.00625 12.5 25 NI NI NI NI NI NI
∆ecm33  (FBEHO41-01A) 15.625 31.25 7.81 15.625 0.00625 0.00625 12.5 25 NI NI NI NI NI NI









CFW Congo red SDS




3.5.2 Determination of cell surface charge 
 
 Alcian blue is a positively charged dye that strongly binds to negative charges on fungal 
cell walls. Binding of Alcian blue (i.e. the reduction of absorbance in the reaction buffer) was 
used to quantify the charge state of cell walls. These assays demonstrated that specifically the 
deletion of ECM33 led to increased Alcian blue binding in the cell wall of C. glabrata, C. 
albicans and S. cerevisiae. This effect was observed in ECM33 deletions (Δecm33 and 
Δpst1/Δecm33 mutants). However, it was not observed in the Δpst1 mutants (Figure 24). In the 





Figure 24. Alcian blue binding of C. glabrata, C. albicans and S. cerevisiae 
Binding of Alcian blue normalized to the respective wild-type strains (=100%). *: statistic test by 
student’s t-test (significance threshold p < 0.05). Error bars represent the mean value calculated 







3.5.3 Determination of cell wall composition 
  
 Fluorescence-activated cell sorting (FACS) assays were used to quantify the binding of 
different substances to the cell wall components glucan and chitin. Alexa-fluor 647-labelled 
wheat germ agglutinin (WGA) was used to stain chitin and Congo red to stain glucan in the 
fungal cell wall. Quantification by FACS analysis demonstrated that ECM33 deleetion (Δecm33 
or Δpst1/Δecm33), but not Δpst1 mutant led to an increased WGA staining in C. glabrata, C. 
albicans and S. cerevisiae (Figure 25 A).  
 Overexpression of CgPST1, CgSPS2 or CgSPS33 in the Δecm33 mutant strain 
(Δecm33:CgPST1, Δecm33:CgSPS2, and Δecm33:CgSPS33) did not compensate the increased 
WGA binding. However, expression of ECM33 from C. albicans and S. cerevisiae rescued this 
phenotype in the ECM33 deletion of C. glabrata (Figure 25 A).  
 Consistantly, in all three species examined, no significant differences of the mutants in 
Congo red binding was observed, implying that the lack of ECM33 does not affect the total 
glucan levels of the cells (Figure 25 B). 
 
3.5.4 Measurement of adherence properties 
 
 To examine the adherence ability of the yeast cells, adherence assays  towards 
polystyrene and silicone were carried out. In addition, the cell surface hydrophobicity was 
determined by measuring relocalization of cells from an aqueous to a hydrophobic phase (octane 
test). These hydrophobicity assays showed that the C. glabrata Δecm33 mutant was significantly 
less hydrophobic as compared to the wild-type and auxotrophic strain. In addition, the C. 
glabrata Δpst1/Δecm33 mutant was found to be significantly less hydrophobic as compared to 
the single Δecm33 mutant. In contrast, the loss of PST1 alone did not affect the hydrophobicity. 
There were no significant differences of cell surface hydrophobicity among the gene deletion 









Figure 25. FACS analysis of WGA and Congo red binding in C. glabrata, C. albicans and S. 
cerevisiae 
Realtive staining of chitin (A: Alexa Fluor
®
 647 conjugated wheat germ agglutinin) and glucan 
(B: Congo Red) normalized to the respective wildtype strains (=100%), as measured by FACS. 
*: statistic test by student’s t-test (significance threshold p < 0.05). Error bars represent the mean 









 In polystyrene adherence assays, the C. glabrata Δecm33 and Δpst1/Δecm33 mutants 
were significantly less adherent as compared to the wild-type and auxotrophic strains. There 
were no significant differences between strains of C. albicans and S. cerevisiae, respectively 
(Figure 26 B).  
In these assays, the results of the hydrophobicity tests show a high correlation to the 
results of polystyrene tests. For example, the strains showing high hydrophobicity properties also 
showed, high polystyrene adherence capacities. 
The silicone adherence capacity of C. glabrata was significantly reduced in the Δecm33 
mutant when compared to the wild-type and auxotrophic strains. Additionally, the double mutant 
Δpst1/Δecm33 showed a further significant reduction of about 60% in adherence towards silicone 
when to the Δecm33 mutant, which was rescued in the respective reconstituted controls.  
Strains of C. glabrata heterologously complemented with CgPST1, CgSPS2, CgSPS22, 
ScECM33 and CaECM33 showed no statistically significant differences when compared to the 
parental Δecm33 strain.  
In C. albicans, the Δecm33 mutant showed a similar reduced silicone adherence capacity. 
In S. cerevisiae this effect was not observed, since the S. cerevisiae wild types did not adhere to 















Figure 26. Adherence properties of C. glabrata, C. albicans and S. cerevisiae. 
Realtive hydrophilicity and adherence proterties normalized to the respective auxotrophic wild-
type strains (=100%), (A): hydrophilicity, (B): polystyrene adherence capacity, and (C): silicone 
adherence capacity. *: statistic test by student’s t-test as (significance threshold p < 0.05 when 
compared to auxotrophic wild-type strain). **: significance threshold p < 0.05 when compared 







3.6  C. glabrata Ecm33 and Pst1 protein expression in P. pastoris 
 
3.6.1 Recombinant pPICZα vector construction  
 
 The pPICZα vecor was used for expression of recombinant Ecm33 and Pst1 proteins 
(EasySelect
TM
 Pichia Expression Kit, Invitrogen). The partial CgECM33 and CgPST1 genes 
without respective signal peptides and ω-sites were amplified and introduced into the pPICZα 
plasmid. The PCR product size of CgECM33 and CgPST1 fragments were 1,150 and 1,183 bp, 
respectively (Figure 27 A).  
 The recombinant pPICZα candidates were verified with double restriction enzyme 
digestion and plasmid DNA sequencing. The recombinant pPICZα:CgECM33 candidate was 
digested with EcoRI and KpnI and the recombinant pPICZα:CgPST1 candidate was confirmed 
by EcoRI and XbaI. The CgECM33 and CgPST1 digested fragments have a size of 1,144 and 
1,177 bp, respectively (Figure 27 B). Confirmed vector plasmids were transformed into the P. 
pastoris strains X33 and GS115.   
 
Figure 27. Amplification of CgECM33 and CgPST1 genes and verification of both 
recombinant pPICZα plasmids 
 
A: PCR products of CgECM33 and CgPST1 genes. Lane 1,4: DNA marker, lane 2: 1,150 bp of 
CgECM33, and lane 4: 1,183 bp of CgPST1. 
B: verification of the recombinant pPICZα:CgECM33 and pPICZα:CgPST1 plasmids by using 
double restriction enzyme digestion. Lane 1: DNA marker, lane 2: natural pPICZα (upper band: 
relaxed form and lower band: supercoiled), lane 3: pPICZα digested with EcoRI/KpnI, lane 4: 





3.6.2 CgEcm33 and CgPst1 proteins expression in P. pastoris   
 
 Resulting from the procedure outlined above, four strains were generated to express 
recombinant gylcosylated CgEcm33 and CgPst1 proteins in P. pastoris (GS115:CgECM33, 
GS115:CgPST1, X33:CgECM33, and X33:CgPST1). All strains were tested for recombinant 
protein expression and subsequently the conditions and time points of protein expression were 
optimized. The results of SDS-PAGE analyses showed that the P. pastoris supernatants from day 
3 had the highest concentration of total proteins and that P. pastoris GS115 expresses both 
CgEcm33 and CgPst1 proteins to a higher extend as compared to the X33 strains (Figure 28). 
Based on these results, the GS115:CgECM33 and GS115:CgPST1 strains were used to express 
the proteins for further studies. 
 In SDS-PAGE analyses, both proteins bands were visible as high molecular weight 
smears between 130 to 55 kDa (compared to the calculated molecular weight deduced from the 
amino acid sequence of the recombinant CgEcm33 and CgPst1 proteins as 41 and 42 kDa, 
respectively). To analyse whether the observed higher molecular weight of the recombinant 
proteins was caused by extensive glycosylation, deglycosylation experiments were performed.   
 Treatment of the recombinant proteins with N-glycosidase (Endo-α-N-
Acetylgalactosaminidase) resulted in a reduced molecular weight from around 100 to 72 kDa to 
approximately, 55 and 60 kDa, respectively.and a more coherent band in SDS-PAGE gels as 
shown in Figure 29. However, no reduction in the molecular weight of both proteins was 
observed when O-glycosidase (PNGase F) was used (Figure 29). 
Similarly, double digestion was little different from treatment with N-glycosidase (Figure 
29). The results indicated that the recombinant Ecm33 and Pst1 proteins which were produced in 
P. pastoris are heavily N-glycosylated as digestion with N-glycosidase resulted in a significant 
reduction of the molecular weight. 
Recombinant Ecm33 and Pst1 proteins were used subsequently for determination of 









Figure 28. CgEcm33 and CgPst1 protein expression in P. pastoris 
All recombinant P. pastoris strains were grown in BMMH media and incubated at 30°C with 
aeration for 2-3 days. Kex2 expression was used as a positive control of the protein expression 
(Lesage, G., Tremblay, M. et al., 2001). The GS115:CgECM33 and GS115:CgPST1 strains were 
used to express the proteins for further studies because of the highest protein production. Three 




Figure 29. CgEcm33 and CgPst1 protein deglycosylation 
 
CgEcm33 and CgPst1 recombinant proteins from P. pastoris were deglycosylated by using N-
glycosidase, O-glycosidase, or by double digestion with N-glycosidae and O-glycosidase. U: 
untreated, N: treatment with N-glycosidase (molecular weight of 36 kDa), O: treatment with O-
glycosidase (molecular weight of 147 kDa), and N/O: double treatment with N-glycosidae and 





3.7 Anti-Ecm33 antibody production 
  
3.7.1 Generation of plasmids for the expression of  recombinant CgEcm33 protein in E. coli 
 
 Ecm33 protein expression in E. coli was performed using the QIAexpressionist™ system 
as described by the manufacturerer. The primers F-LM-pQE and R-LM-pQE were used to 
amplify a 1,150 bp of ECM33 fragment (Figure 30 A) and cloned to the BamHI/PstI linearlized 
pQE30 plasmid. The generated pQE30:CgECM33 plasmid was confirmed using double 
restriction enzyme digestion and plasmid DNA sequencing. The recombinant pQE30:CgECM33 
candidate was digested with BamHI and Pst1. The CgECM33 digested fragment has a size of 
1,144 bp as shown in Figure 30 B. After verification, the pQE30:CgECM33 plasmid was 
transformed to the competent E. coli strain BL-21.  
 
 
Figure 30. Amplification of the CgECM33 gene and verification of the generated 
pQE30:CgECM33plasmids 
 
A: PCR products of CgECM33 gene. Lane 1: DNA marker, lane 2 and 3: 1,150 bp of CgECM33. 
B: verification of the generated pQE30:CgECM33 plasmids by using double restriction enzyme 
digestion. Lane 1: DNA marker, lane 2: circular pQE30:CgECM33 plasmid, lane 3: pQE30 


















Ecm33p = 41.04 kDa 
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3.7.2 CgEcm33 protein expression in E. coli 
  
 Recombinant CgEcm33 protein was expressed in E. coli for production of anti-Ecm33 
polyclonal sera in rabbits. The recombinant CgEcm33 protein produced in E. coli was used for 
immunization rather than the variant produced in P. pastoris because of its lack of glycosylation 
circumventing production of non-specific antibodies to carbohydrate components. The 
transformed E. coli was induced with 1 mM IPTG for 4-5 hours and the His-Tag affinity 
chromatography was used to purify the CgEcm33 protein from cell lysates. 
 During purification, a band corresponding to recombinant CgEcm33 protein was not 
found in the flow through or the washing steps (Figure 31 A). Instead, the recombinant 









Figure 31. Purification of recombinant CgEcm33 by His-tag affinity chromatography 
 









 washing. There is no an expected protein band in all steps.  
B: elution steps; lane 1: protein marker, lane 2-5:1-4 elution, the expected CgEcm33 protein 
band was encountered in all elution steps but the CgEcm33 in 4
th




3.7.3 Anti-Ecm33 antibody production  
 
 Production of anti-Ecm33 polyclonal antisera was performed by Eurogentec, Liège, 
Belgium. The purified recombinant CgEcm33 protein produced in E. coli was immunized in two 
rabbits (code number 22 and 23) by using 100 µg in each immunization. Serum samples of both 
animals were analysed before immunization to exclude the preexistence of antibodies cross 
reacting with CgEcm33 (data not shown). Serum samples were tested for antibody production at 
days 0 (pre-immune serum), 38, 66, and 87 after the first immunization by Western blott analysis 
with the recombinant CgEcm33 proteins produced in E. coli as well as P. pastoris. In addition, 
the recombinant CgPst1 proteins were used to analyse a cross-reaction. The results demonstrated 
that the generated polyclonal anti-Ecm33 antibodies can recognize both recombinant Ecm33 
proteins from E. coli and P. pastoris as shown in Figure 32. Moreover, cross reaction of the anti-
Ecm33 polyclonal antibody from rabbit no. 23 to the Pst1 protein was observed (Figure 32 B). 
 
Figure 32. Western blot analyses of the generated anti-CgEcm33 antisera 
A: testing of CgEcm33 antigen from E. coli and anti-CgEcm33 antisera (titer 1:4,000). Lane 1: 
pre-immune serum, lane 2: serum in 2
nd
 month of rabbit No.22, lane 3: rabbit serum in 2
nd
 month 
of rabbit No.23. The results demonstrate that the immunized serum in 2
nd
 month of two rabbits 
can recognize CgEcm33 antigen purified from E. coli. 
B: testing of CgEcm33 and CgPst1 antigens from P. pastoris and anti-CgEcm33 antisera (titer 
1:4,000). Lane 1: protein marker, lane 2: CgPst1 and rabbit serum No.22, lane 3: CgEcm33 and 
rabbit serum No.22, lane 4: CgPst1 and rabbit serum No. 23, lane 5: CgEcm33 and rabbit serum 
No.23. The results demonstrate that serum from rabbit no. 22 can recognize CgEcm33 only but 




3.8 Cell wall protein release assay 
 
 To investigate a potential loss  of cell wall components in the absence of the  Ecm33 
protein overnight culture supernatants were collected from C. glabrata wild-type and mutant 
strains and concentrated 50-fold (15 ml spin column pore size 10,000 Da). In the concentrated 
culture supernatants total protein concentrations were measured and SDS-PAGE and western 
blot analyses performed to determine a potential release of β-1,6-glucan and/or the abundant 
glucan-bound structural cell wall protein Cwp1. 
 Compared to the wild-type, the C. glabrata ∆ecm33 mutant released both, 1,6- β-glucan 
and Cwp1. The ∆pst1/∆ecm33 double mutant released Cwp1 and 1,6-β-glucan linked protein to a 
larger degree than ∆ecm33 only (Figure 33). 
 
Figure 33. Western blot analyses of culture supernatants 
A: Detection of 1,6-β-glucan linked protein in culture supernatants by western blot with 
monoclonal rabbit anti-β-1,6-glucan antibodies. Note that glucans do not migrate inside the 
separating gel due to their size, but are rather stacked at the top. B: Detection of Cwp1 protein in 
culture supernatants by western blot with polyclonal rabbit anti-Cwp1 antibodies. 
Lane 1: protein marker, lane 2: concentrated culture supernatant of wild-type, lane 3: ∆htl 
(auxotroph), lane 4: ∆pst1, lane 5: ∆ecm33, lane 6: ∆pst1/∆ecm33, lane 7: ∆pst1:CgPST1, lane 8: 
∆ecm33:CgECM33, lane 9: ∆pst1/∆ecm33:CgPST1, lane 10: ∆pst1/∆ecm33:CgECM33 
a
: ratio calculated by the formular of (percent of total protein release ÷ percent of growth rate) x 





3.9 Binding assay 
 
 As the molecular function of the Ecm33 protein family members is unknown, a binding 
assay was performed to investigate whether Ecm33 might actively bind to the cell wall. 
 The results demonstrated that both recombinant Ecm33 and Pst1 proteins bind better to 
the extracted cell walls (ECWs) of the ∆ecm33, Δecm33:truncated CgECM33 and  
∆pst1/∆ecm33 mutants as compared to wild-type and ∆pst1 ECWs (Figure 34). 
 
 
Figure 34. Binding assay 
A: Incubation of the extracted cell walls (ECWs) and Pst1 protein, detection with rabbit serum 
no. 23.  
B: Incubation of the extracted cell walls (ECWs) and Ecm33 protein, detection with rabbit serum 
no. 22.  
Lane 1: protein marker, lane 2: Pst1 protein from P. pastoris in A. or Ecm33 protein from P. 
pastoris in B., lane 3: wild-type ECWs, lane 4: ELISA blocking solution, lane 5: wild-type 
ECWs, lane 6: ∆ecm33 ECWs, lane 7: ∆pst1 ECWs, lane 8: Δecm33:truncated CgECM33 ECWs, 









 The  increased incidence of fungal infections seen over the past decades significantly 
impacts on human public health (Giri, S. and Kindo, A. J., 2012; Mayer, F. L., Wilson, D. et al., 
2013). Among fungal infections, candidiasis is the most frequent and C. glabrata is the second 
most prevalent causative agent of systemic and local candidiasis. C. glabrata infection may 
become difficult to treat because this organism can be highly resistant to anti-mycotic drugs, 
especially the commonly used substance fluconazole (Borg-von Zepelin, M., Kunz, L. et al., 
2007; Pfaller, M. A., Diekema, D. J. et al., 2010). The mortality rate of candidiasis caused from 
C. glabrata infection can be as high as 50% in patients with extended candidemia longer 30 days 
(Das, I., Nightingale, P. et al., 2011). 
 For fungal pathogenesis, the fungal cell wall carries key functions. Among proteins 
localized to the C. glabrata cell wall, the a glycosyl-phosphatidylinositol (GPI)-anchored protein 
Ecm33 is one of the most abundant (de Groot, P. W., Kraneveld, E. A. et al., 2008). Sequence 
homologs of Ecm33 can be found in many fungi, where full genome sequences are available. 
Examples are not only budding yeasts, but also fission yeast, dimorphic fungi, dermatophytes, 
other molds, and plant pathogenic fungi.  
Previous studies showed that Ecm33 proteins was associated with cell wall integrity an 
and biofilm formation, and pathogenicity (Martinez-Lopez, R., Monteoliva, L. et al., 2004; 
Pardo, M., Monteoliva, L. et al., 2004; Chabane, S., Sarfati, J. et al., 2006; Martinez-Lopez, R., 
Park, H. et al., 2006; Romano, J., Nimrod, G. et al., 2006; Martinez-Lopez, R., Nombela, C. et 
al., 2008). Experimental evidence also suggested differences in the biological role of Ecm33 
between, for example, yeast and molds. Furthermore, the exact biochemical function of Ecm33 
in any fungus remains speculative. Because of the clinical impact of the cell wall and the fact 
that Ecm33 homologs were identified experimentally in the cell wall proteome as very abundant 
CWPs in the human pathogen C. glabrata (de Groot, P. W., Kraneveld, E. A. et al., 2008), this 




the results were compared to comprehensive analyses that were carried out with the homologs in 
C. albicans and S. cerevisiae. 
 
4.1 CgECM33 is required for cell fitness, cell wall integrity, and adhesion  
 
 The results from agar drop dilution assays using different cell wall perturbing agents 
demonstrated that the Δecm33:Δecm33 strain of C. albicans and the Δecm33 and Δpst1/Δecm33 
strains of S. cerevisiae were sensitive to Caffeine, Calcofluor white, and Congo red when 
compared to the auxotrophic wild-type in each organism. However, there were no phenotypic 
differences in the Δpst1 mutant of S. cerevisiae compared to the wild type strain. Our results 
confirm  previous studies which showed that the Δecm33 mutant in C. albicans was susceptible 
to Calcofluor white, Congo red and Hygromycin B (Martinez-Lopez, R., Monteoliva, L. et al., 
2004) and Δecm33 and Δpst1/Δecm33 mutants in S. cerevisiae had a cell wall weakness, being  
sensitive to Calcofluor white, Caffeine and Hygromycin B (Pardo, M., Monteoliva, L. et al., 
2004). These results indicate that ECM33 of C. albicans and S. cerevisiae are required for cell 
wall integrity. 
 Surprisingly, all generated mutants in C. glabrata did not show the phenotypic 
differences which were discovered in C. albicans and S. cerevisiae using agar drop dilution 
assays. However, we were able to demonstrate that this observation is based on technical 
limitations of these assays in this organism, as C. glabrata shows a high intrinsic resistance 
towards these substances.  Instead, the Δecm33 and Δpst1/Δecm33 mutants in C. glabrata show 
phenotypes when higher concentrations of cell wall perturbing agents are used. Therefore, 
additional broth micro-dilution assays were developed to explore the generated mutant strains in 
C. glabrata. These assays showed that the Δecm33 mutant in C. glabrata was more susceptible 
to Calcofluor white and Congo red. The Δpst1/Δecm33 double mutant was even more susceptible 
(approx. 4-times more sensitive when compared to the wild-type) towards Calcofluor white, 
Congo red, SDS and Hygromycin B. Taken together, these results indicate that ECM33 in C. 
glabrata is also required for cell wall integrity. 
 The Δecm33 mutants in C. albicans, S. cerevisiae and C. glabrata had a defect in growth 




C condition. The completed revertant of C. 




respectively. These data indicate that ECM33 is an essential protein for growth in the three 
organisms. Moreover, we found that the Δpst1/Δecm33 double mutant in C. glabrata and S. 
cerevisiae had slower growth rates than the Δecm33 mutant in both media and at both 
temperatures. These data indicate synergistic effects upon deletion of ECM33 and PST1. 
However, no significant differences of growth were observed in the Δpst1 mutant of S. cerevisiae 
and C. glabrata when compared to its auxotrophic wild-type. Taken together, Ecm33 is a key 
protein in the cell wall of C. glabrata that determines not only the cell wall strength, but also 
influences the growth rate of these organisms. 
 Furthermore, the analyses on the generated C. glabrata strains showed that the Δecm33 
mutant displays significantly increased hydrophilic surface properties when compared to the 
wild-type or auxotrophic wild-type strain. Also, the Δpst1/Δecm33 double mutant was found to 
be more hydrophilic as compared to the Δecm33 single mutant. The results from polystyrene 
adherence capacity assays correlated with hydrophobicity surface properties of the strains: more 
hydrophilic (less hydrophobic) isolates showed less polystyrene adherence capacity and 
consequently, the C. glabrata  mutants Δecm33 and Δpst1/Δecm33 lost polystyrene adherence 
capacity. In contrast, no phenotypic alterations were observed in terms of hydrophilicity and/or 
polystyrene adherence capacity in the C. albicans and S. cerevisiae mutants. However, it should 
be noted that the parental strains that were used to generate the mutants in C. albicans and S. 
cerevisiae do not have any ability to adhere to polystyrene. Therefore, it is difficult to compare 
and correlate ECM33 function and the influence on polystyrene adherence in these organisms. 
 The results of silicone adherence assays demonstrated that the Δecm33 mutant of C. 
glabrata has a lower adherence capacity to this material as compared to the wild-type strain. The 
Δpst1/Δecm33 double mutant is reduced approximately 60% when compared to wild-type and 
also shows a significant reduction when compared to the Δecm33 mutant. The Δecm33 mutant of 
C. albicans is also affected in silicone adherence capacity, but this phenotype was not observed 
in the S. cerevisiae mutants.  
 The results obtained with C. glabrata confirm that ECM33 affects important adherence 
capacities of human pathogenic Candida spp. and this assumption is further supported by our 
results with the C. albicans mutants and a previous study using a C. albicans Δecm33 mutant. 
This study showed that in C. albicans the Δecm33 mutant displays a lower adherence and 




(Martinez-Lopez, R., Park, H. et al., 2006; Rouabhia, M., Semlali, A. et al., 2012). Therefore, we 
conclude that beyond cell wall strength and growth, ECM33 contributes significantly to the 
adherence capacities of human pathogenic yeasts. As a consequence ECM33 might be 
considered a gene associated with virulence in Candida spp. 
 
4.2 ECM33 of C. glabrata, C. albicans, and S. cerevisiae have a similar function but not 
identical functions. 
   
  To explore the function of CgEcm33-family a set of complementation mutants were 
generated and analyzed. In the CgΔecm33 strain (i) the homologs of C. albicans (CaECM33) and 
S. cerevisiae (ScECM33), (ii) the ECM33 homologs of C. glabrata (PST1, SPS2 and SPS22) and 
(ii) a truncated version CgECM33 without the GPI-anchor motif were introduced in order to 
explore if the phenotypes of the CgΔecm33 mutant can be rescued. All generated strains were 
tested for growth, cell wall strength, hydrophobicity and adhesion to polystyrene and silicone. 
Gene expression analysis confirmed that in both constructed strains, Δecm33:CaECM33 and 
Δecm33:ScECM33 could be expressed at a levels that compare to approx. 90% of the wild-type 
ECM33 gene in C. glabrata. Interestingly, the phenotypes of the two complemented strains were 
very similar to the C. glabrata wild-type, indicating that both heterologous homologs can 
compensate the role of CgECM33 in terms of cell wall fitness, growth and cell wall composition. 
However, in the adherence assays and the Alcian blue staining assay, the phenotypes of the 
CgΔecm33 mutant could not fully be rescued on all experiments. This might indicate that subtle 
differences do exist in the multilayered function of the ECM33 genes that manifest e.g. in the 
assembly and/or incorporation of cell wall proteins (mediating negative surface charge) 
including the cell wall adhesins. Another option would be that the Ecm33 protein acts as a 
adhesion protein itself, but this seems to be not very likely as the S. cerevisiae Δecm33 mutant 
expressing CaECM33 does not adhere to or penetrate epithelial cell whereas the auxotrophic 
wild type strain of C. albicans does (Martinez-Lopez, R., Park, H. et al., 2006). 
 The next question was whether the homologous genes of the CgECM33 family can 
replace the function of CgECM33. To answer this question, a second set of overexpression 
strains were generated in the CgΔecm33 mutant (Δecm33:CgPST1, Δecm33:CgSPS2, and 




showed that there were significantly increased levels of up-regulation in the three overexpression 
strains, but the expression levels of the integrated genes were found only 20%, 15% and 10%, 
respectively above the wild-type level. We also excluded that a negative feedback regulation is 
observed in the ECM33 gene family of C. glabrata and that the gene product from an introduced 
over-expression plasmid induces the down-regulation of the natural expression of the respective 
gen homologs. Moreover, the phenotypic results from the three complemented strains displayed 
very similar phenotypes as the Δecm33 mutant indicating, that the other three members of this 
family can not compensate the function of CgECM33. These data support the idea that the 
proteins do not show functional redundancy. However, at this point it cannot be ruled out, that 
the experimental level of overexpression was too low to induce noticeable compensatory effects 
or that a few overlapping, but so far unrecognized activities do exist within this family. In 
agreement with these data in a previous study in S. cerevisiae high level expression of ScPST1 in 
a ScΔecm33 mutant (Δecm33/Yep352-PST1 strain) could not compensate or rescue the 
phenotype of the Δecm33 strain, when tested with the cell wall perturbing agents Calcofluor 
white, Congo red and Caffeine. However, a very slight compensation was observed for the 
hygromycin B phenotype (Pardo, M., Monteoliva, L. et al., 2004). 
 When the truncated version of CgECM33 without the GPI-anchor motif was reintroduced 
in the CgΔEcm33 mutant all the phenotypes observed in the deletion strain could not be rescued. 
This confirms that the anchor and most likely covalent cell wall incorporation of ECM33 is 
necessary for its proper function (see below). 
 
4.3 Ecm33 is associated with alterations in the chemical composition of the cell wall  
 
 As outlined above, the results of the Alcian blue staining experiments showed that 
ECM33 deletion (Δecm33 and Δpst1/Δecm33) resulted in an increase of negative charges on the 
cell surface of C. glabrata pointing to an altered composition of the cell wall (possibly mediated 
by macromolecules such as proteins, mannans, glucans, and chitins). In contrast, this effect was 
not observed when only PST1 was deleted in C. glabrata. 
 To further investigate these compositional alterations staining of glucan and chitin in the 
yeast cells walls using wheat-germ agglutinin (WGA–Alexafluor 647 conjugate) and Congo red, 




staining experiments in the three organisms demonstrated that the Δecm33 and Δpst1/Δecm33 
mutants, but not the Δpst1 mutant, had more chitin in cell wall when compared to wild-type 
auxotrophic strain. Again, when the homologs of the CgECM33-family were over expressed in 
the C. glabrata Δecm33 mutant (Δecm33:CgPST1, Δecm33:CgSPS2, and Δecm33:CgSPS22)  a 
reduction of the level of chitin was not observed showing that this alteration in cell wall 
composition can not be rescued by these ECM33 family members. In contrast, ECM33 from C. 
albicans and S. cerevisiae could complement this phenotype in C. glabrata. The observed 
increase in the chitin level of the mutant might have different reasons: (i) ECM33 might be 
involved in the incorporation of  chitin in the cell wall. Consistent with this, a  previous report on 
C. albicans showed that Δchs (chitin synthase) 2, Δchs3, Δchs2/Δchs3, and Δecm33 mutants 
could not release melanin pigment to the environment after induction with L-3,4-
dihydroxyphenylalanine (L-DOPA) and N-acetylglucosamine, while the auxotroph NGY152 
could do that. This indicates that a functional ECM33 gene is required for the production of cell 
wall chitin components involved in melanin externalization (Walker, C. A., Gomez, B. L. et al., 
2010). These analyses were also performed with the generated C. glabrata strains, however no 
melanin externalization, neither in wild-type strains, nor in the mutants was observed in this 
organism (data not shown). (ii) The increased chitin might also reflect an indirect and 
compensational effect induced by the cell wall weakening in the CgΔecm33 mutant. Generally, 
when fungi face a disruption of cell wall strength, an up-regulation of the cell wall integrity-
pathway and subsequently a compensatory increase in chitin production is observed to prevent 
cell wall collapse (Kapteyn, J. C., Van Egmond, P. et al., 1999). In agreement with our findings, 
in two previous studies, S. cerevisiae Δecm33 mutants display an enhanced Calcofluor white 
fluorescence intensity due to high chitin content on cell wall (de Groot, P. W., Ruiz, C. et al., 
2001; Pardo, M., Monteoliva, L. et al., 2004). 
 The relative quantification of the glucan level in the cell wall exhibited no significant 
differences between any of the C. glabrata strains. Also alterations of the glucan level in cell 
wall were not observed in the mutants of C. albicans and S. cerevisiae. These data imply that the 
lack of ECM33 does not affect the total glucan level on the cell wall.  
  However, using Western blot analyses we observed that in CgΔecm33 mutant released 
more β-1,6-glucan linked protein to the culture supernatant as compared to wild-type strain and 




observation was also made in the ScΔecm33 mutant (de Groot, P. W., Ruiz, C. et al., 2001). In 
addition, the abundant cell wall protein Cwp1 of C. glabrata was detected in the culture 
supernatant of Δecm33 and Δpst1/Δecm33 mutants using Western blot analyis. This result is 
similar to the result of a study by Pardo et al. in Δecm33 mutant of S. cereviaise. This group 
showed that the ScCwp1 protein is released to the culture medium in the bakers yeast mutant. In 
contrast, in a further study by De Groot’s group the ScCwp1 protein was not identified in the 
culture supernatant of Δecm33 mutant of S. cereviaise. However, both groups noticed the release 
of Pir2 cell wall proteins, β-1,6-glucan (Pardo, M., Monteoliva, L. et al., 2004) and also  β-1,3-
glucan (de Groot, P. W., Ruiz, C. et al., 2001) to the culture supernatant. In summary, the altered 
cell wall composition and the loss of cell wall components and proteins of the mutants indicate 
that ECM33 plays crucial role in the assembly of the cell wall in C. glabrata influencing its 
architecture and function. 
 
4.4 A model for the role of Ecm33 for the fungal cell wall  
 
 As shown above, deletion of ECM33, but not PST1, has a profound effect on the stability 
and architecture of the cell wall, not only in C. glabrata, but also in other fungi such as C. 
albicans and S. cerevisiae. The cells are significantly more susceptible to cell (wall) perturbing 
agents, reflecting a loss of cell wall rigidity. Furthermore, the composition of the cell wall is 
altered in a way that more chitin is present (potentially representing a compensatory mechanism), 
and β-1,6-glucan containing material is lost to the environment. Most likely as a consequence of 
β-1,6-glucan loss, also adhesion is reduced, since adhesins are in turn linked to β-1,6-glucan 
through GPI-anchors. In total, this leads to reduced fitness, and probably also to reduced 
virulence, as shown at least for C. albicans (Martinez-Lopez, R., Monteoliva, L. et al., 2004; 
Martinez-Lopez, R., Park, H. et al., 2006; Martinez-Lopez, R., Nombela, C. et al., 2008; 
Rouabhia, M., Semlali, A. et al., 2012).  
 These phenotypes can be explained, if we assume that Ecm33 provides a crucial link 






Figure 35. Hypothetical model of Ecm33 contribution to cell wall structure 
 
4.5 Exploring the molecular function of Ecm33 
 
 Three possibilities of Ecm33 protein function can be proposed based on our experimental 
results: Model I: Ecm33 could be a structural protein, where Ecm33 is linked to the cell wall 
through the GPI anchor and the activity of another protein; Model II: Ecm33 could be a lectin, 
binding carbohydrate moieties of the cell wall; Model III: Ecm33 itself could be an enzyme, 
linking 1,6-glucan containing material to the cell wall (Figure 36). 
To explore these options, different molecular tools were set up to help deducing data that 
support any of the model proposed above: active recombinant forms of Ecm33 and Pst1 proteins 
were made in P. pastoris, antisera were raised against recombinant Ecm33 expressed and 
purified from E. coli, and to explore the role of the GPI-anchor, C. glabrata Δecm33 strain 







Figure 36. Models of potential Ecm33 functions 
 
 If Ecm33 was an enzyme, the GPI anchor should not be needed for full function. We 
therefore re-investigated all of the phenotypes observed in the Δecm33 mutant in a strain 
expressing a truncated, GPI-anchor-less form (Δecm33:truncated CgECM33). As described 
above, the phenotypic results of Δecm33:truncated CgECM33 were similar to Δecm33 mutant 
while the strain Δecm33:CgECM33 was conformable to wild-type, indicating that a truncated 
form cannot, even partially, complement the loss of  ECM33. This strongly argues against an 
enzymatic function of Ecm33. It also implies that the GPI-anchor of Ecm33 protein is a 
necessary part for its function. 
 In case that, ECM33 was a structural component or a lectin, the protein should be found 
in the cell wall of Δecm33:truncated CgECM33 despite the lack of its GPI anchor. In the case of 
a structural component, Ecm33 should be covalently linked, and not extractable, in the case of a 
lectin it should bind the cell wall reversibly. To address this, antisera against recombinant Ecm33 




the recombinant form of the protein, they failed to recognize any epitope in proteins or cell walls 
extracted from C. glabrata. 
Nevertheless, the antisera were able to recognize recombinant Ecm33 produced in P. 
pastoris. One of the antisera also cross-reacted with recombinant Pst1, enabling the study of both 
proteins. Binding assays of the two recombinant proteins were carried out on extracted cell walls 
(ECWs) from the different mutant strains. These experiments demonstrated that CgEcm33 and 
CgPst1 protein both bind ECWs from ∆ecm33, Δecm33:truncated CgECM33 and ∆pst1/∆ecm33 
better than wild-type and ∆pst1 ECWs. From this, we can propose that the lack of Ecm33, but 
not Pst1 protein in the cell wall leaves epitopes which can be actively and reversibly bound by 
both Ecm33 and Pst1. 
In order to identify potential binding partners, initial competition binding experiments 
with glucose and N-acetylglucosamine (Supplements, chapter 6.4) were carried out. Preliminary 
results from these experiments suggest a stronger inhibition of Ecm33 binding to the cell wall by 
glucose than N-acetylglucosamine. 
 According to our results, it can be summarized that Ecm33 in C. glabrata is associated 
with cell growth, cell wall assembly and integrity, chemical composition of the cell wall and the 
adherence capacity of the organism. The complementation experiments show that the Ecm33 
proteins form C. albicans, S. cerevisiae and C. glabrata have overlapping, but not identical 
functions, as many phenotypes that were observed in the CgΔecm33 mutant could be restored by 
heterologous expression. Interestingly, the adherence phenotype and the altered surface charge 
could not be complemented by heterologous expression indicating that CgEcm33 shows subtle 
functional differences possibly in mediating the proper incorporation of cell wall proteins by 
acting as a lectin. The results also show that the other members of the Ecm33 protein family in 
C. glabrata (Pst1, Sps2, and Sps22) are functionally not redundant and are not upregulated in 












 Candida glabrata is the second most frequent cause of local and systemic human 
candidiasis and infections with this species are difficult to treat because of frequent azole 
resistance. C. glabrata infections have high mortality rates in immunocompromised patients. 
During pathogenesis, the cell wall is of particular importance, because it holds key functions 
such as adhesion and countering of immune defenses. 
 Next to the structural proteins of the Cwp1-family, Ecm33 and Pst1 have been identified 
as the most abundant GPI-anchored proteins in the cell wall, but their functions are largely 
unclear. In C. albicans and S. cerevisiae, the ECM33 deletion mutants show partially 
overlapping phenotypes suggesting defects in cell wall assembly. Therefore, gene disruption and 
complementation experiments were conducted on these genes in C. glabrata. 
 The results of these experiments show that, similar to C. albicans and S. cerevisiae, the 
C. glabrata ∆ecm33 and ∆pst1/∆ecm33 mutants are susceptible to most cell wall perturbing 
agents. The mutants have a more negatively charged cell wall surface and release Cwp1 protein 
and β-1,6-glucan containing material to the environment. Most importantly, as a consequence the 
mutants lose some adherence capacities, which is of particular interest in terms of C. glabrata 
pathogenicity. With the notable exceptions of the adherence phenotype and the surface charge, 
the phenotypes are rescued by introduction of ScECM33 and CaEMC33. In contrast, the 
phenotypes could not be compensated in the ∆ecm33 mutant of C. glabrata by overexpression of 
the remaining members of the C. glabrata ECM33-family (CgPST1, CgSPS2 and CgSPS22). 
However, we can not rule out that this is due to technical limitations of the experimental 
approaches. From the overall phenotypic data, we can propose that Ecm33 probably is involved 
in the linkage of β-1,6-glucan to the cell wall. If β-1,6-glucan is lost, so is its carrier function for 
effector proteins, resulting in the observed phenotypes. The generated phenotypic data also 
enabled to develope different hypothetical models for the biological function of Ecm33 in C. 




 These analyses now make it possible to further characterize the biological role of this 
very abundant cell wall protein, for example using comprehensive binding assays, glycochip 
experiments and proteomic work on the cell wall and secreted proteomes of the generated 
mutants. The improved understanding of the cell wall in C. glabrata will enable to characterize 











6.1 DNA sequence of CgECM33 for cloning in E. coli 
 
 DNA sequecnce of C. glabrata was taken from online genome database 
(http://www.genolevures.org) and the restriction enzyme was chosen by checking via NEBcutter 
V2.0 (http://tools.neb.com/NEBcutter2/). 
 Online program http://web.expasy.org/translate/ is used to translate DNA sequence to 
protein sequence. The expected molecular weight of CgEcm33 protein was calculated from 
amount of amino acids via http://www.sciencegateway.org/tools/proteinmw.htm. The 
recombinant CgEcm33 protein expressed in E. coli consists of 397 amino acids that this protein 
has a molecular weight as 41.04 kDa. The CgEcm33 protein for cloning in E. coli is a partial 




















Annotation; atg and tga: start and stop codon, gray box: 6XHis-tag, gray box: restriction site, 
black box: primer site, and underline: ECM33 coding sequence 
 
- Protein sequence of CgEcm33 expressed in E.coli 
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6.3 Deglycosylation of CgEcm33 and CgPst1 protein and western blot analysis 
 
 In experiment 3.6.3 protein deglycosylation, we want to know to exact molecular weight 
of Ecm33 after deglycosylation. Therefore, we performed the same experiment and used the 
western blot. The result showed that anti-Ecm33 monoclonal antibody from rabbit can recognize 
the glycosylation (Figure 38). 
 
 
Figure 38. Deglycosylation of CgEcm33 and CgPst1 proteins and Western blot analysis  
Western blot analysis after for CgEcm33 and CgPst1 proteins deglycosylation by double 
digestion of N-glycosidae and O-glycosidase (N/O: CgEcm33 or CgPst1 was incubated with 
both glycosidase). Lane 1: protein marker, lane 2: CgPst1 without treatment, lane 3: CgPst1 with 
N- and O-glycosidase, lane 4: CgEcm33 without treatment, lane 5: CgEcm33 with N- and O-
glycosidase, lane 6: CgPst1 without treatment, lane 7: CgPst1 with N- and O-glycosidase, lane 8: 
CgEcm33 without treatment, and lane 9: CgEcm33 with N- and O-glycosidase. The serum rabbit 








6.4 The preliminary results of competitive inhibition assay 
 
 
Figure 39. Glucose competitive inhibition assay 
 
20 µl of the extracted cell walls (ECWs; 20 mg/ml) were incubated with ELISA blocking 
solution, incubated with or without glucose (10 µl of 0.01, 0.1, or 1 M) and then added Ecm33 
protein (250 µg/ml) and washed to remove unbound protein. SDS-PAGE electrophoresis and 
western blot analysis were performed to determine binding complex. 
Lane 1: protein marker, lane 2: 1 M of glucose, lane 3: Ecm33 protein from P. pastoris, lane 4: 
co-incubation without glucose competitor, lane 5: co-incubation with 0.01 M glucose competitor, 
lane 6: co-incubation with 0.1 M glucose competitor, and lane 7: co-incubation with 1 M glucose 
competitor (lane 4-7 are co-incuabion between CgEcm33 expressed in P. pastoris with Δecm33 











Figure 40. N-acetylglucosamine competitive inhibition assay 
 
20 µl of the extracted cell walls (ECWs; 20 mg/ml) were incubated with ELISA blocking 
solution, incubated with or without N-acetylglucosamine (NAG; 10 µl of 0.01, 0.1, or 1 M) and 
then added Ecm33 protein (250 µg/ml) and washed to remove unbound protein. SDS-PAGE 
electrophoresis and western blot analysis were performed to determine binding complex. 
Lane 1: protein marker, lane 2: 1 M of N-acetylglucosamine, lane 3: Ecm33 protein from P. 
pastoris, lane 4: co-incubation without N-acetylglucosamine competitor, lane 5: co-incubation 
with 0.01 M N-acetylglucosamine competitor, lane 6: co-incubation with 0.1 M N-
acetylglucosamine competitor, and lane 7: co-incubation with 1 M N-acetylglucosamine 
competitor (lane 4-7 are co-incuabion between CgEcm33 expressed in P. pastoris with Δecm33 
ECWs, and N-acetylglucosamine was used to prevent binding between CgEcm33 expressed in P. 
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